| BY ORDER OF THE BOARD /s/ Margaret Henry Margaret Henry Company Secretary April | | | Registered Office 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RX, United Kingdom Registered in England and Wales No 09338148 | |
| | | Page | | |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | | | ||
| | | | 9 | | | |
| | | | 10 | | | |
| | | | 11 | | | |
| | | | 12 | | | |
| | | | 13 | | | |
| | | | 14 | | | |
| | | | 15 | | | |
| | | | 16 | | | |
| | | | 17 | | | |
| | | | 18 | | | |
| | | | 19 | | | |
| | | | 20 | | | |
| | | | 22 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | A-1 | | | |
| | | | | |
| Proposal | | | Description of Proposal | | | Board’s Recommendation | |
| 1 | | | Re-election of | | | FOR | |
| 2 | | | Re-election of | | | FOR | |
| 3 | | | Re-election of Lawrence Alleva as a director | | | FOR | |
| 4 | | | Re-election of Priti Hegde as a director | | | FOR | |
| 5 | | | Re-election of Kristen Hege as a director | | | FOR | |
| 6 | | | Re-election of Garry Menzel as a director | | | FOR | |
| 7 | | | Re-appointment of KPMG LLP as the Company’s auditors, to hold office until the conclusion of the next annual general meeting of shareholders | | | FOR | |
| | | Authorization for the Audit Committee to determine our auditors’ remuneration for the fiscal year ending December 31, | | | FOR | | |
| | | To adopt the U.K. statutory annual accounts and reports for the fiscal year ended December 31, | | | FOR | | |
| | | Approval of the compensation of our named executive officers for the year ended December 31, | | | FOR | | |
| | | Approval of our U.K. statutory directors’ annual report on remuneration for the year ended December 31, | | | FOR | | |
| | | Approval of our U.K. directors’ remuneration policy, which is set forth as Part II of Annex A, and which, if approved, will take effect upon the conclusion of the Meeting. | | | FOR | | |
| 13 | | | Authorization for the Board of Directors to allot shares or to grant rights to subscribe for or convert any security into shares up to a maximum aggregate nominal amount of | | | FOR | |
| | | Empowering the Board of Directors to allot equity securities for cash up to a maximum aggregate nominal amount of | | | FOR | |
Fees | | December 31, 2022 ($) | | December 31, 2021 ($) | | | December 31, 2023 ($) | | December 31, 2022 ($) | | ||||||||||||||||
Audit Fees(1) | | | | 1,374,000 | | | | | 1,218,000 | | | | | | 1,026,000 | | | | | 1,188,000 | | | ||||
Audit-related Fees(2) | | | | 72,000 | | | | | 91,000 | | | | | | 386,000 | | | | | 258,000 | | | ||||
Tax Fees(3) | | | | — | | | | | — | | | | | | — | | | | | — | | | ||||
All Other Fees(4) | | | | — | | | | | — | | | | | | — | | | | | — | | | ||||
Total | | | | 1,446,000 | | | | | 1,309,000 | | | | | | 1,412,000 | | | | | 1,446,000 | | |
Name | | | Age | | | Position | |
David M. Mott | | | | | Chairman of the Board of Directors | | |
Andrew Allen, M.D, Ph. D. | | | 57 | | | Non-Executive Director | |
Lawrence M. Alleva | | | | | Non-Executive Director | | |
Ali Behbahani, M.D. | | | |||||
| | Non-Executive Director | | ||||
John Furey | | | | | Non-Executive Director | | |
| | | | Non-Executive Director | | ||
| | | | Non-Executive Director | | ||
Garry Menzel, Ph.D | | | 59 | | | Non-Executive Director | |
Adrian Rawcliffe | | | | | Chief Executive Officer and Director | |
| Country of Principal Executive Offices: | | | England | | |||||||||
| Foreign Private Issuer | | | No | | |||||||||
| Disclosure Prohibited under Home Country Law | | | No | | |||||||||
| Total Number of Directors | | | |
| | Female | | Male | | Non-Binary | | Did Not Disclose Gender | | | Female | | Male | | Non-Binary | | Did Not Disclose Gender | | ||||||||
Part I: Gender Identity | | | | | | | | | | | | | | | | | | | ||||||||
Directors | | 1 | | 7 | | 0 | | 0 | | | 2 | | 7 | | 0 | | 0 | | ||||||||
Part II: Demographic Background | | | | | | | | | | | | | | | | | | | ||||||||
Underrepresented Individual in Home Country Jurisdiction | | 1 | | | | | | | | | 2 | | | | | | | | ||||||||
LGBTQ+ | | 0 | | | | | | | | | 0 | | | | | | | | ||||||||
Did Not Disclose Demographic Background | | 0 | | | | | | | | | 0 | | | | | | | |
Name | | | Audit | | | Remuneration | | | Corporate Governance and Nominating | | | Research and Development | |
David M. Mott | | | | | | Chair | | | Chair | | | | |
Andrew Allen, M.D. | | | | | | X | | | | | | X | |
Lawrence M. Alleva | | | Chair | | | | | | | | | | |
Ali Behbahani, M.D. | | | | | | | | | X | | |||
| X | | |||||||||||
John Furey | | | X | | | X | | | | | | | |
| | | | | | | | X | | | X | | |
Kristen Hege, M.D. | | | | | | | | | | | | Chair | |
Garry Menzel, Ph.D. | | | X | | | | | | | | | | |
| | | Ordinary Shares Beneficially Owned | | |||||||||
Name of Beneficial Owner | | | Number | | | Percent | | ||||||
5% Shareholders | | | | | | | | | | | | | |
Matrix Capital Management Master Fund L.P(1) | | | | | 233,845,110 | | | | | | 23.53 | | |
Baillie Gifford & Co(2) | | | | | 103,019,634 | | | | | | 10.37 | | |
New Enterprise Associates(3) | | | | | 102,478,672 | | | | | | 10.31 | | |
Baker Bros. Advisors, L.P.(4) | | | | | 58,985,262 | | | | | | 5.94 | | |
Named Executive Officers and Directors | | | | | | | | | | | | | |
Adrian Rawcliffe(5) | | | | | 15,656,150 | | | | | | 1.58 | | |
William Bertrand(6) | | | | | 7,901,234 | | | | | | * | | |
Gavin Wood(7) | | | | | 3,801,734 | | | | | | * | | |
Elliot Norry, M.D.(8) | | | | | 2,505,900 | | | | | | * | | |
Cintia Piccina(9) | | | | | 1,451,802 | | | | | | * | | |
Ali Behbahani, M.D.(10) | | | | | 104,087,563 | | | | | | 10.47 | | |
James Noble(11) | | | | | 17,843,233 | | | | | | 1.80 | | |
Elliott Sigal, M.D., Ph.D.(12) | | | | | 2,364,324 | | | | | | * | | |
Lawrence M. Alleva(13) | | | | | 2,232,797 | | | | | | * | | |
David M. Mott(14) | | | | | 2,001,724 | | | | | | * | | |
Barbara Duncan(15) | | | | | 1,367,562 | | | | | | * | | |
John Furey(16) | | | | | 1,100,748 | | | | | | * | | |
Executive Officers | | | | | | | | | | | | | |
Helen Tayton-Martin, Ph.D.(17) | | | | | 11,197,200 | | | | | | 1.13 | | |
John Lunger(18) | | | | | 4,391,025 | | | | | | * | | |
Joanna Brewer, Ph.D(19) | | | | | 1,733,762 | | | | | | * | | |
Named Executive Officers, Directors and Executives as a Group (15 persons) | | | | | 179,636,758 | | | | | | 18.08 | | |
| | | Ordinary Shares Beneficially Owned | | |||||||||
Name of Beneficial Owner | | | Number | | | Percent | | ||||||
5% Shareholders | | | | | | | | | | | | | |
Matrix Capital Management Master Fund L.P(1) | | | | | 233,845,110 | | | | | | 15.25 | | |
EcoR1 Capital, LLC(2) | | | | | 164,424,420 | | | | | | 10.73 | | |
New Enterprise Associates(3) | | | | | 102,478,672 | | | | | | 6.68 | | |
Baillie Gifford & Co(4) | | | | | 95,472,840 | | | | | | 6.23 | | |
Named Executive Officers and Directors | | | | | | | | | | | | | |
Adrian Rawcliffe(5) | | | | | 20,343,080 | | | | | | 1.33 | | |
Helen Tayton-Martin(6) | | | | | 12,984,350 | | | | | | * | | |
William Bertrand(7) | | | | | 9,497,212 | | | | | | * | | |
Gavin Wood(8) | | | | | 5,967,870 | | | | | | * | | |
Elliot Norry, M.D.(9) | | | | | 4,097,928 | | | | | | * | | |
Ali Behbahani, M.D.(10) | | | | | 104,824,613 | | | | | | 6.84 | | |
Garry Menzel(11) | | | | | 14,229,810 | | | | | | * | | |
Lawrence M. Alleva(12) | | | | | 3,048,864 | | | | | | * | | |
David M. Mott(13) | | | | | 3,002,163 | | | | | | * | | |
John Furey(14) | | | | | 1,600,748 | | | | | | * | | |
Andrew Allen(15) | | | | | 411,064 | | | | | | * | | |
Priti Hegde(16) | | | | | 349,423 | | | | | | * | | |
Kristen Hege(17) | | | | | — | | | | | | — | | |
Executive Officers | | | | | | | | | | | | | |
John Lunger(18) | | | | | 6,043,168 | | | | | | * | | |
Joanna Brewer, Ph.D(19) | | | | | 2,868,542 | | | | | | * | | |
Cintia Piccina(20) | | | | | 1,451,802 | | | | | | * | | |
Named Executive Officers, Directors and Executives as a Group (16 persons) | | | | | 190,720,637 | | | | | | 12.44 | | |
| | 2022 Cash Compensation | | | 2023 Cash Compensation | | ||||||||
Board of Directors | | | $ | 40,000 | | | | | $ | 40,000 | | | ||
Chairman (additional retainer) | | | $ | 30,000 | | | | | $ | 35,000 | | | ||
Audit Committee Chair (additional retainer) | | | $ | 20,000 | | | | | $ | 20,000 | | | ||
Remuneration Committee Chair (additional retainer) | | | $ | 15,000 | | | | | $ | 15,000 | | | ||
Corporate Governance and Nominating Committee Chair (additional retainer) | | | $ | 10,000 | | | | | $ | 10,000 | | | ||
Audit Committee member/non-Chair (additional retainer) | | | $ | 10,000 | | | | | $ | 10,000 | | | ||
Remuneration Committee member/non-Chair (additional retainer) | | | $ | 7,500 | | | | | $ | 7,500 | | | ||
Corporate Governance and Nominating Committee member/non-Chair (additional retainer) | | | $ | 5,000 | | | | | $ | 5,000 | | |
Name | | | Fees Earned or paid in cash$(1) | | | Option awards($)(2) | | | Total ($) | | |||||||||
David M. Mott(3) | | | | | — | | | | | | 208,542 | | | | | | 208,542 | | |
Lawrence Alleva(4) | | | | | — | | | | | | 170,109 | | | | | | 170,109 | | |
Ali Behbahani(5) | | | | | — | | | | | | 153,638 | | | | | | 153,638 | | |
Barbara Duncan(6) | | | | | 50,000 | | | | | | 104,225 | | | | | | 154,225 | | |
John Furey(7) | | | | | 57,500 | | | | | | 104,225 | | | | | | 161,725 | | |
James Noble(8) | | | | | 17,532 | | | | | | 148,148 | | | | | | 165,680 | | |
Elliott Sigal(9) | | | | | — | | | | | | 153,638 | | | | | | 153,638 | | |
Tal Zaks(10) | | | | | 47,500 | | | | | | 104,225 | | | | | | 151,725 | | |
Name | | | Fees Earned or paid in cash $ | | | Option awards ($)(1) | | | Total ($) | | |||||||||
David M. Mott(2) | | | | | — | | | | | | 174,831 | | | | | | 174,831 | | |
Andrew Allen(3) | | | | | 23,750 | | | | | | 59,754 | | | | | | 83,504 | | |
Lawrence Alleva(4) | | | | | — | | | | | | 128,800 | | | | | | 128,800 | | |
Ali Behbahani(5) | | | | | — | | | | | | 111,539 | | | | | | 111,539 | | |
Barbara Duncan(6) | | | | | 20,833 | | | | | | — | | | | | | 20,833 | | |
John Furey(7) | | | | | 57,500 | | | | | | 59,754 | | | | | | 117,254 | | |
Priti Hegde(8) | | | | | 22,500 | | | | | | 59,754 | | | | | | 82,254 | | |
Kristen Hege(9) | | | | | 6,667 | | | | | | 65,967 | | | | | | 72,634 | | |
Garry Menzel(10) | | | | | — | | | | | | 117,293 | | | | | | 117,293 | | |
James Noble(11) | | | | | — | | | | | | — | | | | | | — | | |
Elliott Sigal(12) | | | | | — | | | | | | 111,539 | | | | | | 111,539 | | |
Tal Zaks(13) | | | | | 11,875 | | | | | | — | | | | | | 11,875 | | |
Name | | | Age | | | Position | |
Adrian Rawcliffe | | | | | Chief Executive Officer and Director | | |
Gavin Wood | | | | | Chief Financial Officer | | |
Helen Tayton-Martin, Ph.D | | | | | Chief Business & Strategy Officer | | |
William Bertrand | | | | | Chief Operating Officer | | |
John Lunger | | | | | Chief Patient Supply Officer | | |
Elliot Norry, M.D | | | | | Chief Medical Officer | | |
Joanna Brewer, Ph.D | | | | | Chief Scientific Officer | | |
Cintia Piccina | | | 51 | | | Chief Commercial Officer | |
| 2023/24 | | | 2022/2023 | | |||
| | | Achilles Therapeutics plc | | ||||
| | | Agenus Inc. | | ||||
| | | Atara Biotherapeutics, | |||||
| ||||||||
| Autolus Therapeutics plc | | | Autolus Therapeutics plc | | |||
| Bicycle Therapeutics plc | | | | ||||
| bluebird bio, Inc. | | | | ||||
| Caribou Biosciences, Inc. | | | Immunocore Holding plc | | |||
| ||||||||
| | ImmunoGen, | | |||||
| | | Inovio Pharmaceuticals, Inc. | | ||||
| Inovio Pharmaceuticals, Inc. | | | Instil Bio, Inc. | | |||
| Instil Bio, Inc. | | | MacroGenics, Inc. | | |||
| Lyell Immunopharma, Inc. | | | Nkarta, Inc. | | |||
| MacroGenics, Inc. | | | |
| 2023/24 | | | 2022/2023 | |
| Nkarta, Inc. | | | | |
| Oxford Biomedica plc | | | | |
| Poseida Therapeutics, Inc. | | | | |
| Precigen, Inc. | | | | |
| Precision Biosciences, Inc. | | | ||
| |||||
| Sana Biotechnology, Inc. | | | | |
| Sangamo Therapeutics, Inc. | | | | |
| | | | |
Name | | 2022 Annual Base Salary ($) | | 2021 Annual Base Salary ($) | | % Increase | | | 2023 Annual Base Salary ($) | | 2022 Annual Base Salary ($) | | % Increase | | ||||||||||||||||||||||||
Adrian Rawcliffe | | | | 650,000 | | | | | 617,050 | | | | | 5.3% | | | | | | 650,000 | | | | | 650,000 | | | | | — | | | ||||||
Gavin Wood(1) | | | | 419,618 | | | | | 409,384 | | | | | 2.5% | | | | | | 441,402 | | | | | 441,402 | | | | | — | | | ||||||
William Bertrand | | | | 468,179 | | | | | 456,760 | | | | | 2.5% | | | | | | 468,179 | | | | | 468,179 | | | | | — | | | ||||||
Helen Tayton-Martin(1) | | | | 449,004 | | | | | 449,004 | | | | | — | | | ||||||||||||||||||||||
Elliot Norry | | | | 446,355 | | | | | 425,100 | | | | | 5.0% | | | | | | 446,355 | | | | | 446,355 | | | | | — | | | ||||||
Cintia Piccina(2) | | | | 445,000 | | | | | — | | | | | — | | |
Name | | | 2022 Target Annual Cash Bonus Opportunity % | | | 2022 Target Annual Cash Bonus Opportunity ($) | | ||||||
Adrian Rawcliffe | | | | | 60% | | | | | | 390,000 | | |
Gavin Wood(1) | | | | | 45% | | | | | | 188,828 | | |
William Bertrand | | | | | 45% | | | | | | 210,681 | | |
Name | | 2022 Target Annual Cash Bonus Opportunity % | | 2022 Target Annual Cash Bonus Opportunity ($) | | | 2023 Target Annual Cash Bonus Opportunity % | | 2023 Target Annual Cash Bonus Opportunity ($) | | ||||||||||||||||
Adrian Rawcliffe | | | | 60% | | | | | 390,000 | | | |||||||||||||||
Gavin Wood(1) | | | | 45% | | | | | 198,631 | | | |||||||||||||||
William Bertrand | | | | 45% | | | | | 210,681 | | | |||||||||||||||
Helen Tayton-Martin(1) | | | | 45% | | | | | 202,052 | | | |||||||||||||||
Elliot Norry | | | | 45% | | | | | 200,860 | | | | | | 45% | | | | | 200,860 | | | ||||
Cintia Piccina(2) | | | | 45% | | | | | 183,563 | | |
Name | | 2022 Target Annual Cash Bonus Opportunity ($) | | 2022 Calculated Cash Bonus Payment (Based on 60% Performance) ($) | | 2022 Actual Annual Cash Bonus Payment ($) | | | 2023 Target Annual Cash Bonus Opportunity ($) | | 2023 Actual Cash Bonus Payment ($) | | ||||||||||||||||||||
Adrian Rawcliffe | | | | 390,000 | | | | | 234,000 | | | | | — | | | | | | 390,000 | | | | | 370,500 | | | |||||
Gavin Wood(1) | | | | 188,828 | | | | | 113,297 | | | | | 56,648 | | | | | | 198,631 | | | | | 188,700 | | | |||||
William Bertrand | | | | 210,681 | | | | | 126,409 | | | | | 63,204 | | | | | | 210,681 | | | | | 200,147 | | | |||||
Helen Tayton-Martin(1) | | | | 202,052 | | | | | 191,949 | | | |||||||||||||||||||||
Elliot Norry | | | | 200,860 | | | | | 120,516 | | | | | 60,258 | | | | | | 200,860 | | | | | 190,817 | | | |||||
Cintia Piccina(2) | | | | 183,563 | | | | | 110,138 | | | | | 55,069 | | |
Named Executive Officer | | | Options for ordinary shares (#) | | | RSU-Style Options for ordinary shares (#) | | | Equity Awards (Aggregate Grant Date Fair Value) ($) | | |||||||||
Adrian Rawcliffe | | | | | 4,690,224 | | | | | | 1,798,272 | | | | | | 1,716,163 | | |
Gavin Wood | | | | | 1,407,072 | | | | | | 507,984 | | | | | | 504,895 | | |
William Bertrand | | | | | 1,407,072 | | | | | | 517,056 | | | | | | 507,762 | | |
Helen Tayton-Martin | | | | | 1,407,072 | | | | | | 511,320 | | | | | | 505,950 | | |
Elliot Norry | | | | | 1,407,072 | | | | | | 507,600 | | | | | | 504,774 | | |
Named Executive Officer | | | Options for ordinary shares (#) | | | RSU-Style Options for ordinary shares (#) | | | Equity Awards (Aggregate Grant Date Fair Value) ($) | | |||||||||
Adrian Rawcliffe | | | | | 4,690,224 | | | | | | 1,047,480 | | | | | | 2,714,882 | | |
Gavin Wood | | | | | 1,407,072 | | | | | | 314,256 | | | | | | 814,474 | | |
William Bertrand | | | | | 1,407,072 | | | | | | 314,256 | | | | | | 814,474 | | |
Elliot Norry | | | | | 2,110,608 | | | | | | 471,360 | | | | | | 1,221,696 | | |
Cintia Piccina | | | | | 3,376,992 | | | | | | 1,089,384 | | | | | | 1,588,155 | | |
| | | Ordinary Shares Beneficially Owned as of December 31, | | ||||||
Named Executive Officer | | | Number(1) | | | Value(2) | | |||
Adrian Rawcliffe | | | | | | | | | ||
Gavin Wood | | | | | | | | | ||
William Bertrand | | | | | | | | | ||
Helen Tayton-Martin | | | | | 2,588,964 | | | | 0.76 x base salary | |
Elliot Norry | | | | | | | | 0.08 | ||
|
| | | | The Remuneration Committee of the Board of Directors | |
| | | | David M. Mott, Chairman Andrew Allen John Furey | |
Name and Principal Position | | Year | | Salary ($) | | Option awards ($)(3) | | Non-equity incentive plan compensation ($)(4) | | Bonus ($) | | All other compensation ($) | | Total ($) | | | Year | | Salary ($) | | Option awards ($)(3) | | Non-equity incentive plan compensation ($)(4) | | All other compensation ($)(5) | | Total ($) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Adrian Rawcliffe (1) Chief Executive Officer | | | | | 2022 | | | | | 650,000 | | | | | 2,714,882 | | | | | — | | | | | | | | | | 43,645(5) | | | | | 3,408,527 | | | | | | | 2023 | | | | | 650,000 | | | | | 1,716,163 | | | | | 370,500 | | | | | 37,378 | | | | | 2,774,041 | | | |||||||||||
| | | 2021 | | | | | 617,050 | | | | | 3,207,291 | | | | | 351,719 | | | | | | | | | | 38,941(6) | | | | | 4,215,001 | | | | | | 2022 | | | | | 650,000 | | | | | 2,714,882 | | | | | — | | | | | 43,645 | | | | | 3,408,527 | | | ||||||||||||||
| | | 2020 | | | | | 574,000 | | | | | 1,715,346 | | | | | 378,840 | | | | | | �� | | | | 33,416(7) | | | | | 2,701,602 | | | | | | 2021 | | | | | 617,050 | | | | | 3,207,291 | | | | | 351,719 | | | | | 38,941 | | | | | 4,215,001 | | | ||||||||||||||
Gavin Wood (2) Chief Financial Officer | | | | | 2022 | | | | | 419,618 | | | | | 814,474 | | | | | 56,648 | | | | | | | | | | 31,955(8) | | | | | 1,322,695 | | | | | | | 2023 | | | | | 441,402 | | | | | 504,895 | | | | | 188,700 | | | | | 36,242 | | | | | 1,171,239 | | | |||||||||||
| | | 2021 | | | | | 409,384 | | | | | 1,069,101 | | | | | 175,012 | | | | | | | | | | 31,598(9) | | | | | 1,685,094 | | | | | | 2022 | | | | | 441,402 | | | | | 814,474 | | | | | 59,589 | | | | | 33,614 | | | | | 1,349,078 | | | ||||||||||||||
| | | 2020 | | | | | 299,549(10) | | | | | 990,268 | | | | | 148,276 | | | | | 42,361(11) | | | | | 23,164(12) | | | | | 1,503,618 | | | | | | 2021 | | | | | 430,636 | | | | | 1,069,101 | | | | | 184,097 | | | | | 33,238 | | | | | 1,717,072 | | | ||||||||||||||
William Bertrand Chief Operating Officer | | | | | 2022 | | | | | 468,179 | | | | | 814,474 | | | | | 63,204 | | | | | | | | | | 42,415(13) | | | | | 1,388,271 | | | | | | | 2023 | | | | | 468,179 | | | | | 507,762 | | | | | 200,147 | | | | | 39,012 | | | | | 1,215,100 | | | |||||||||||
| | | 2021 | | | | | 456,760 | | | | | 1,069,101 | | | | | 195,265 | | | | | | | | | | 35,062(14) | | | | | 1,756,188 | | | | | | 2022 | | | | | 468,179 | | | | | 814,474 | | | | | 63,204 | | | | | 42,415 | | | | | 1,388,271 | | | ||||||||||||||
| | | 2020 | | | | | 443,456 | | | | | 857,661 | | | | | 219,511 | | | | | | | | | | 30,485(15) | | | | | 1,551,113 | | | | | | 2021 | | | | | 456,760 | | | | | 1,069,101 | | | | | 195,265 | | | | | 35,062 | | | | | 1,756,188 | | | ||||||||||||||
Helen Tayton-Martin Chief Business & Strategy Officer | | | | | 2023 | | | | | 449,004 | | | | | 505,950 | | | | | 191,949 | | | | | 36,451 | | | | | 1,183,352 | | | ||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2022 | | | | | 449,004 | | | | | 814,474 | | | | | 60,615 | | | | | 36,201 | | | | | 1,360,293 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2021 | | | | | 438,052 | | | | | 1,069,101 | | | | | 187,267 | | | | | 44,232 | | | | | 1,738,652 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||
Elliot Norry Chief Medical Officer | | | | | 2022 | | | | | 446,355 | | | | | 1,221,696 | | | | | 60,258 | | | | | | | | | | 42,436(16) | | | | | 1,770,746 | | | | | | | 2023 | | | | | 446,355 | | | | | 504,774 | | | | | 190,817 | | | | | 39,022 | | | | | 1,180,968 | | | |||||||||||
| | | 2021 | | | | | 425,100 | | | | | 1,069,101 | | | | | 181,730 | | | | | | | | | | 35,062(17) | | | | | 1,710,993 | | | | | | 2022 | | | | | 446,355 | | | | | 1,221,696 | | | | | 60,258 | | | | | 42,436 | | | | | 1,770,746 | | | ||||||||||||||
| | | 2020 | | | | | 390,000 | | | | | 204,881 | | | | | 160,119 | | | | | 117,000(18) | | | | | 33,650(19) | | | | | 905,650 | | | | | | 2021 | | | | | 425,100 | | | | | 1,069,101 | | | | | 181,730 | | | | | 35,062 | | | | | 1,710,993 | | | ||||||||||||||
Cintia Piccina Chief Commmercial Officer | | | | | 2022 | | | | | 407,917(20) | | | | | 1,588,155 | | | | | 55,069 | | | | | 100,000(21) | | | | | 34,454(22) | | | | | 2,185,595 | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Named Executive Officer | | | 401(k) Matching Contributions ($) | | | Pension Allowance Payment ($) | | | Medical, Dental and Life, Insurance ($) | | | Tax Planning Reimbursement ($) | | | Total All Other Compensation ($) | | |||||||||||||||
Adrian Rawcliffe | | | | | 15,250 | | | | | | — | | | | | | 18,579 | | | | | | 3,549 | | | | | | 37,378 | | |
Gavin Wood | | | | | — | | | | | | 26,484 | | | | | | 9,758 | | | | | | — | | | | | | 36,242 | | |
William Bertrand | | | | | 15,250 | | | | | | — | | | | | | 23,762 | | | | | | — | | | | | | 39,012 | | |
Helen Tayton-Martin | | | | | — | | | | | | 26,939 | | | | | | 9,511 | | | | | | — | | | | | | 36,451 | | |
Elliot Norry | | | | | 15,250 | | | | | | — | | | | | | 23,772 | | | | | | — | | | | | | 39,022 | | |
Name | | First date some or all options are exercisable(1) | | Number of Securities Underlying Unexercised Options (#) Exercisable(2) | | Number of Securities Underlying Unexercised Options(#) Unexercisable(2) | | Option Exercise Price ($/Sh)(3) | | Option Expiration Date | | | First date some or all options are exercisable(1) | | Number of Securities Underlying Unexercised Options (#) Exercisable(2) | | Number of Securities Underlying Unexercised Options(#) Unexercisable(2) | | Option Exercise Price ($/Sh)(3) | | Option Expiration Date | | ||||||||||||||||||||||||||||||||||||||||
Adrian Rawcliffe | | | | | 03/16/2016(4) | | | | | 3,000,000 | | | | | 0 | | | | | 0.61 | | | | | 03/16/2025 | | | |||||||||||||||||||||||||||||||||||
| | | 01/18/2017(4) | | | | | 939,948 | | | | | 0 | | | | | 1.08 | | | | | 01/18/2026 | | | | | | | 03/16/2016(4) | | | | | 3,000,000 | | | | | 0 | | | | | 0.64 | | | | | 03/16/2025 | | | ||||||||||
| | | 01/13/2018(4) | | | | | 2,072,976 | | | | | 0 | | | | | 0.71 | | | | | 01/13/2027 | | | | | | 01/18/2017(4) | | | | | 939,948 | | | | | 0 | | | | | 1.13 | | | | | 01/18/2026 | | | |||||||||||
| | | 01/12/2019(4) | | | | | 687,984 | | | | | 0 | | | | | 1.16 | | | | | 01/12/2028 | | | | | | 01/13/2018(4) | | | | | 2,072,976 | | | | | 0 | | | | | 0.75 | | | | | 01/13/2027 | | | |||||||||||
| | | 01/04/2020 | | | | | 0 | | | | | 70,224 | | | | | 0.0012 | | | | | 01/04/2029 | | | | | | 01/12/2019(4) | | | | | 687,984 | | | | | 0 | | | | | 1.22 | | | | | 01/12/2028 | | | |||||||||||
| | | 01/04/2020 | | | | | 1,231,541 | | | | | 26,203 | | | | | 0.85 | | | | | 01/04/2029 | | | | | | 01/04/2020(4) | | | | | 1,257,744 | | | | | 0 | | | | | 0.89 | | | | | 01/04/2029 | | | |||||||||||
| | | 06/27/2020 | | | | | 0 | | | | | 35,112 | | | | | 0.0012 | | | | | 06/27/2029 | | | | | | 06/27/2020(4) | | | | | 628,872 | | | | | 0 | | | | | 0.67 | | | | | 06/27/2029 | | | |||||||||||
| | | 06/27/2020 | | | | | 550,248 | | | | | 78,624 | | | | | 0.64 | | | | | 06/27/2029 | | | | | | 09/01/2020(4) | | | | | 628,872 | | | | | 0 | | | | | 0.28 | | | | | 09/01/2029 | | | |||||||||||
| | | 09/01/2020 | | | | | 0 | | | | | 35,112 | | | | | 0.0012 | | | | | 09/01/2029 | | | | | | 01/16/2021 | | | | | 2,463,129 | | | | | 52,407 | | | | | 0.73 | | | | | 01/16/2030 | | | |||||||||||
| | | 09/01/2020 | | | | | 510,945 | | | | | 117,927 | | | | | 0.27 | | | | | 09/01/2029 | | | | | | 01/16/2021 | | | | | 0 | | | | | 140,448 | | | | | 0.0013 | | | | | 01/16/2030 | | | |||||||||||
| | | 01/16/2021 | | | | | 1,834,245 | | | | | 681,291 | | | | | 0.69 | | | | | 01/16/2030 | | | | | | 01/11/2022 | | | | | 0 | | | | | 364,080 | | | | | 0.0013 | | | | | 01/11/2031 | | | |||||||||||
| | | 01/16/2021 | | | | | 0 | | | | | 280,896 | | | | | 0.0012 | | | | | 01/16/2030 | | | | | | 01/11/2022 | | | | | 2,377,375 | | | | | 883,025 | | | | | 0.97 | | | | | 01/11/2031 | | | |||||||||||
| | | 01/11/2022 | | | | | 0 | | | | | 546,120 | | | | | 0.0012 | | | | | 01/11/2031 | | | | | | 01/12/2023 | | | | | 0 | | | | | 785,610 | | | | | 0.0013 | | | | | 01/12/2032 | | | |||||||||||
| | | 01/11/2022 | | | | | 1,562,275 | | | | | 1,698,125 | | | | | 0.92 | | | | | 01/11/2031 | | | | | | 01/12/2023 | | | | | 2,247,366 | | | | | 2,442,858 | | | | | 0.56 | | | | | 01/12/2032 | | | |||||||||||
| | | 01/12/2023 | | | | | 0 | | | | | 1,047,480 | | | | | 0.0012 | | | | | 01/12/2032 | | | | | | 01/17/2024 | | | | | 0 | | | | | 4,690,224 | | | | | 0.33 | | | | | 01/17/2033 | | | |||||||||||
| | | 01/12/2023 | | | | | 0 | | | | | 4,690,224 | | | | | 0.53 | | | | | 01/12/2032 | | | | | | 01/17/2024 | | | | | 0 | | | | | 1,798,272 | | | | | 0.0013 | | | | | 01/17/2033 | | | |||||||||||
Gavin Wood | | | | | 04/01/2021 | | | | | 1,666,600 | | | | | 833,400 | | | | | 0.44 | | | | | 04/01/2030 | | | | | | | 04/01/2021 | | | | | 2,291,560 | | | | | 208,440 | | | | | 0.46 | | | | | 04/01/2030 | | | ||||||||
| | | 04/01/2021 | | | | | 282,500 | | | | | 282,500 | | | | | 0.0012 | | | | | 04/01/2030 | | | | | | 04/01/2021 | | | | | 423,750 | | | | | 141,250 | | | | | 0.0013 | | | | | 04/01/2030 | | | |||||||||||
| | | 01/11/2022 | | | | | 60,678 | | | | | 182,034 | | | | | 0.0012 | | | | | 01/11/2031 | | | | | | 01/11/2022 | | | | | 121,356 | | | | | 121,356 | | | | | 0.0013 | | | | | 01/11/2031 | | | |||||||||||
| | | 01/11/2022 | | | | | 520,766 | | | | | 566,050 | | | | | 0.92 | | | | | 01/11/2031 | | | | | | 01/11/2022 | | | | | 792,470 | | | | | 294,346 | | | | | 0.97 | | | | | 01/11/2031 | | | |||||||||||
| | | 01/12/2023 | | | | | 0 | | | | | 314,256 | | | | | 0.0012 | | | | | 01/12/2032 | | | | | | 01/12/2023 | | | | | 78,564 | | | | | 235,692 | | | | | 0.0013 | | | | | 01/12/2032 | | | |||||||||||
| | | 01/12/2023 | | | | | 0 | | | | | 1,407,072 | | | | | 0.53 | | | | | 01/12/2032 | | | | | | 01/12/2023 | | | | | 674,178 | | | | | 732,894 | | | | | 0.56 | | | | | 01/12/2032 | | | |||||||||||
Gavin Wood | | | | 01/17/2024 | | | | | 0 | | | | | 1,407,072 | | | | | 0.33 | | | | | 01/17/2033 | | | ||||||||||||||||||||||||||||||||||||
| | | 01/17/2024 | | | | | 0 | | | | | 314,256 | | | | | 0.0013 | | | | | 01/17/2033 | | | |||||||||||||||||||||||||||||||||||||
| | | 01/17/2024 | | | | | 0 | | | | | 193,728 | | | | | 0.0013 | | | | | 01/17/2033 | | | |||||||||||||||||||||||||||||||||||||
| | | | 03/15/2018(4) | | | | | 3,407,904 | | | | | 0 | | | | | 0.79 | | | | | 03/15/2027 | | | | | | | 03/15/2018(4) | | | | | 3,407,904 | | | | | 0 | | | | | 0.83 | | | | | 03/15/2027 | | | |||||||||
| | | 01/12/2019(4) | | | | | 644,976 | | | | | 0 | | | | | 1.16 | | | | | 01/12/2028 | | | | | | 01/12/2019(4) | | | | | 644,976 | | | | | 0 | | | | | 1.22 | | | | | 01/12/2028 | | | |||||||||||
| | | 01/04/2020 | | | | | 0 | | | | | 56,190 | | | | | 0.0012 | | | | | 01/04/2029 | | | | | | 01/04/2020(4) | | | | | 1,006,224 | | | | | 0 | | | | | 0.89 | | | | | 01/04/2029 | | | |||||||||||
| | | 01/04/2020 | | | | | 985,261 | | | | | 20,963 | | | | | 0.85 | | | | | 01/04/2029 | | | | | | 01/16/2021 | | | | | 1,231,541 | | | | | 26,203 | | | | | 0.73 | | | | | 01/16/2030 | | | |||||||||||
| | | 01/16/2021 | | | | | 917,105 | | | | | 340,639 | | | | | 0.69 | | | | | 01/16/2030 | | | | | | 01/16/2021 | | | | | 0 | | | | | 70,224 | | | | | 0.0013 | | | | | 01/16/2030 | | | |||||||||||
| | | 01/16/2021 | | | | | 0 | | | | | 140,448 | | | | | 0.0012 | | | | | 01/16/2030 | | | | | | 01/11/2022 | | | | | 0 | | | | | 121,356 | | | | | 0.0013 | | | | | 01/11/2031 | | | |||||||||||
William Bertrand | | | | 01/11/2022 | | | | | 0 | | | | | 182,034 | | | | | 0.0012 | | | | | 01/11/2031 | | | | | | 01/11/2022 | | | | | 792,470 | | | | | 294,346 | | | | | 0.97 | | | | | 01/11/2031 | | | ||||||||||
| | | 01/11/2022 | | | | | 520,766 | | | | | 566,050 | | | | | 0.92 | | | | | 01/11/2031 | | | | | | 01/12/2023 | | | | | 0 | | | | | 235,692 | | | | | 0.0013 | | | | | 01/12/2032 | | | |||||||||||
| | | 01/12/2023 | | | | | 0 | | | | | 314,256 | | | | | 0.0012 | | | | | 01/12/2032 | | | | | | 01/12/2023 | | | | | 674,178 | | | | | 732,894 | | | | | 0.56 | | | | | 01/12/2032 | | | |||||||||||
| | | 01/12/2023 | | | | | 0 | | | | | 1,407,072 | | | | | 0.53 | | | | | 01/12/2032 | | | | | | 01/17/2024 | | | | | 0 | | | | | 1,407,072 | | | | | 0.33 | | | | | 01/17/2033 | | |
Name | | First date some or all options are exercisable(1) | | Number of Securities Underlying Unexercised Options (#) Exercisable(2) | | Number of Securities Underlying Unexercised Options(#) Unexercisable(2) | | Option Exercise Price ($/Sh)(3) | | Option Expiration Date | | | First date some or all options are exercisable(1) | | Number of Securities Underlying Unexercised Options (#) Exercisable(2) | | Number of Securities Underlying Unexercised Options(#) Unexercisable(2) | | Option Exercise Price ($/Sh)(3) | | Option Expiration Date | | ||||||||||||||||||||||||||||||||||||||||
Helen Tayton-Martin | | | | | 12/19/2015(4) | | | | | 1,750,000 | | | | | 0 | | | | | 0.4529 | | | | | 12/19/2024 | | | |||||||||||||||||||||||||||||||||||
| | | 01/18/2017(4) | | | | | 939,948 | | | | | 0 | | | | | 1.13 | | | | | 01/18/2026 | | | |||||||||||||||||||||||||||||||||||||
| | | 01/13/2018(4) | | | | | 2,072,976 | | | | | 0 | | | | | 0.75 | | | | | 01/13/2027 | | | |||||||||||||||||||||||||||||||||||||
| | | 01/12/2019(4) | | | | | 687,984 | | | | | 0 | | | | | 1.22 | | | | | 01/12/2028 | | | |||||||||||||||||||||||||||||||||||||
| | | 01/12/2019(4) | | | | | 153,648 | | | | | 0 | | | | | 0.0013 | | | | | 01/12/2028 | | | |||||||||||||||||||||||||||||||||||||
| | | 01/04/2020(4) | | | | | 224,724 | | | | | 0 | | | | | 0.0013 | | | | | 01/04/2029 | | | |||||||||||||||||||||||||||||||||||||
| | | 01/04/2020(4) | | | | | 1,006,224 | | | | | 0 | | | | | 0.89 | | | | | 01/04/2029 | | | |||||||||||||||||||||||||||||||||||||
| | | 01/16/2021 | | | | | 1,231,541 | | | | | 26,203 | | | | | 0.73 | | | | | 01/16/2030 | | | |||||||||||||||||||||||||||||||||||||
| | | 01/16/2021 | | | | | 210,672 | | | | | 70,224 | | | | | 0.0013 | | | | | 01/16/2030 | | | |||||||||||||||||||||||||||||||||||||
| | | 01/11/2022 | | | | | 121,356 | | | | | 121,356 | | | | | 0.0013 | | | | | 01/11/2031 | | | |||||||||||||||||||||||||||||||||||||
| | | 01/11/2022 | | | | | 792,470 | | | | | 294,346 | | | | | 0.97 | | | | | 01/11/2031 | | | |||||||||||||||||||||||||||||||||||||
| | | 01/12/2023 | | | | | 78,564 | | | | | 235,692 | | | | | 0.0013 | | | | | 01/12/2032 | | | |||||||||||||||||||||||||||||||||||||
| | | 01/12/2023 | | | | | 674,178 | | | | | 732,894 | | | | | 0.56 | | | | | 01/12/2032 | | | |||||||||||||||||||||||||||||||||||||
| | | 01/17/2024 | | | | | 0 | | | | | 1,407,072 | | | | | 0.33 | | | | | 01/17/2033 | | | |||||||||||||||||||||||||||||||||||||
| | | 01/17/2024 | | | | | 0 | | | | | 314,256 | | | | | 0.0013 | | | | | 01/17/2033 | | | |||||||||||||||||||||||||||||||||||||
| | | 01/17/2024 | | | | | 0 | | | | | 197,064 | | | | | 0.0013 | | | | | 01/17/2033 | | | |||||||||||||||||||||||||||||||||||||
Elliot Norry | | | | | 01/18/2017(4) | | | | | 200,000 | | | | | 0 | | | | | 1.08 | | | | | 01/18/2026 | | | | | | | 01/18/2017(4) | | | | | 200,000 | | | | | 0 | | | | | 1.13 | | | | | 01/18/2026 | | | ||||||||
| | | 01/13/2018(4) | | | | | 63,024 | | | | | 0 | | | | | 0.71 | | | | | 01/13/2027 | | | | | | 01/13/2018(4) | | | | | 63,024 | | | | | 0 | | | | | 0.75 | | | | | 01/13/2027 | | | |||||||||||
| | | 07/07/2018(4) | | | | | 300,000 | | | | | 0 | | | | | 0.75 | | | | | 07/07/2027 | | | | | | 07/07/2018(4) | | | | | 300,000 | | | | | 0 | | | | | 0.79 | | | | | 07/07/2027 | | | |||||||||||
| | | 01/12/2019(4) | | | | | 79,824 | | | | | 0 | | | | | 1.16 | | | | | 01/12/2028 | | | | | | 01/12/2019(4) | | | | | 79,824 | | | | | 0 | | | | | 1.22 | | | | | 01/12/2028 | | | |||||||||||
| | | 01/04/2020 | | | | | 0 | | | | | 13,422 | | | | | 0.0012 | | | | | 01/04/2029 | | | | | | 01/04/2020(4) | | | | | 79,824 | | | | | 0 | | | | | 0.89 | | | | | 01/04/2029 | | | |||||||||||
| | | 01/04/2020 | | | | | 78,161 | | | | | 1,663 | | | | | 0.85 | | | | | 01/04/2029 | | | | | | 01/16/2021 | | | | | 197,400 | | | | | 4,200 | | | | | 0.73 | | | | | 01/16/2030 | | | |||||||||||
| | | 01/16/2021 | | | | | 147,000 | | | | | 54,600 | | | | | 0.69 | | | | | 01/16/2030 | | | | | | 01/16/2021 | | | | | 0 | | | | | 33,900 | | | | | 0.0013 | | | | | 01/16/2030 | | | |||||||||||
| | | 01/16/2021 | | | | | 0 | | | | | 67,800 | | | | | 0.0012 | | | | | 01/16/2030 | | | | | | 01/11/2022 | | | | | 792,470 | | | | | 294,346 | | | | | 0.97 | | | | | 01/11/2031 | | | |||||||||||
| | | 01/11/2022 | | | | | 520,766 | | | | | 566,050 | | | | | 0.92 | | | | | 01/11/2031 | | | | | | 01/11/2022 | | | | | 0 | | | | | 121,356 | | | | | 0.0013 | | | | | 01/11/2031 | | | |||||||||||
| | | 01/11/2022 | | | | | 0 | | | | | 182,034 | | | | | 0.0012 | | | | | 01/11/2031 | | | | | | 01/12/2023 | | | | | 0 | | | | | 353,520 | | | | | 0.0013 | | | | | 01/12/2032 | | | |||||||||||
| | | 01/12/2023 | | | | | 0 | | | | | 471,360 | | | | | 0.0012 | | | | | 01/12/2032 | | | | | | 01/12/2023 | | | | | 1,011,300 | | | | | 1,099,308 | | | | | 0.56 | | | | | 01/12/2032 | | | |||||||||||
| | | 01/12/2023 | | | | | 0 | | | | | 2,110,608 | | | | | 0.53 | | | | | 01/12/2032 | | | | | | 01/17/2024 | | | | | 0 | | | | | 1,407,072 | | | | | 0.33 | | | | | 01/17/2033 | | | |||||||||||
Cintia Piccina | | | | | 01/31/2023 | | | | | 0 | | | | | 3,376,992 | | | | | 0.40 | | | | | 01/31/2032 | | | |||||||||||||||||||||||||||||||||||
| | | 01/31/2023 | | | | | 0 | | | | | 754,200 | | | | | 0.0012 | | | | | 01/31/2032 | | | |||||||||||||||||||||||||||||||||||||
Elliot Norry | | | | | 01/17/2024 | | | | | 0 | | | | | 314,256 | | | | | 0.0013 | | | | | 01/17/2033 | | | |||||||||||||||||||||||||||||||||||
| | | 01/17/2024 | | | | | 0 | | | | | 193,344 | | | | | 0.0013 | | | | | 01/17/2033 | | |
| | Option Awards | | | Option Awards | | ||||||||||||||||||||
Name | | Number of Shares Acquired on Exercise (#)(1) | | Value Realized on Exercise ($)(2) | | | Number of Shares Acquired on Exercise (#)(1) | | Value Realized on Exercise ($)(2) | | ||||||||||||||||
Adrian Rawcliffe | | | | 83,558 | | | | | 273,278 | | | | | | 120,801 | | | | | 199,161 | | | ||||
Gavin Wood | | | | — | | | | | — | | | | | | — | | | | | — | | | ||||
William Bertrand | | | | 37,182 | | | | | 132,353 | | | | | | 44,276 | | | | | 76,949 | | | ||||
Helen Tayton-Martin | | | | — | | | | | — | | | |||||||||||||||
Elliot Norry | | | | 20,237 | | | | | 70,860 | | | | | | 37,640 | | | | | 65,024 | | | ||||
Cintia Piccina | | | | 55,864 | | | | | 98,666 | | |
Name | | Benefit(1) | | Termination without Cause or Resignation for Good Reason Not in Connection with a Change in Control ($) | | Termination without Cause or Resignation for Good Reason in Connection with a Change in Control ($) | | | Benefit(1) | | Termination without Cause or Resignation for Good Reason Not in Connection with a Change in Control ($) | | Termination without Cause or Resignation for Good Reason in Connection with a Change in Control ($) | | ||||||||||||||||||
Adrian Rawcliffe | | | Lump Sum Cash Severance Payment | | | | 487,500 | | | | | 650,000 | | | | | Lump Sum Cash Severance Payment | | | | 487,500 | | | | | 650,000 | | | ||||
| Lump Sum Bonus Payment(2) | | | | — | | | | | — | | | | Lump Sum Bonus Payment(2) | | | | 370,500 | | | | | 370,500 | | | |||||||
| Vesting Acceleration(3) | | | | — | | | | | 487,864 | | | | Vesting Acceleration(3) | | | | — | | | | | 404,253 | | | |||||||
| Health Insurance Premiums(4) | | | | 14,413 | | | | | 19,217 | | | | Health Insurance Premiums(4) | | | | 12,434 | | | | | 16,578 | | | |||||||
| Benefit Total | | | | 501,913 | | | | | 1,157,081 | | | | Benefit Total | | | | 870,434 | | | | | 1,441,331 | | | |||||||
Gavin Wood | | | Lump Sum Cash Severance Payment | | | | 314,714 | | | | | 419,618 | | | | | Lump Sum Cash Severance Payment | | | | 331,052 | | | | | 441,402 | | | ||||
| Lump Sum Bonus Payment(2) | | | | 56,648 | | | | | 56,648 | | | | Lump Sum Bonus Payment(2) | | | | 188,700 | | | | | 188,700 | | | |||||||
| Vesting Acceleration(3) | | | | — | | | | | 188,563 | | | | Vesting Acceleration(3) | | | | — | | | | | 131,716 | | | |||||||
| Health Insurance Premiums(4) | | | | 2,001 | | | | | 2,668 | | | | Health Insurance Premiums(4) | | | | 7,319 | | | | | 9,758 | | | |||||||
| Benefit Total | | | | 373,363 | | | | | 667,497 | | | | Benefit Total | | | | 527,070 | | | | | 667,497 | | | |||||||
William Bertrand | | | Lump Sum Cash Severance Payment | | | | 351,134 | | | | | 468,179 | | | | | Lump Sum Cash Severance Payment | | | | 351,134 | | | | | 468,179 | | | ||||
| Lump Sum Bonus Payment(2) | | | | 63,204 | | | | | 63,204 | | | | Lump Sum Bonus Payment(2) | | | | 200,147 | | | | | 200,147 | | | |||||||
| Vesting Acceleration(3) | | | | — | | | | | 167,772 | | | | Vesting Acceleration(3) | | | | — | | | | | 123,606 | | | |||||||
| Health Insurance Premiums(4) | | | | 18,621 | | | | | 24,828 | | | | Health Insurance Premiums(4) | | | | 15,854 | | | | | 21,138 | | | |||||||
| Benefit Total | | | | 432,959 | | | | | 723,983 | | | | Benefit Total | | | | 567,135 | | | | | 813,070 | | | |||||||
Helen Tayton-Martin | | | Lump Sum Cash Severance Payment | | | | 336,753 | | | | | 449,004 | | | ||||||||||||||||||
| Lump Sum Bonus Payment(2) | | | | 191,949 | | | | | 191,949 | | | ||||||||||||||||||||
| Vesting Acceleration(3) | | | | — | | | | | 122,856 | | | ||||||||||||||||||||
| Health Insurance Premiums(4) | | | | 7,133 | | | | | 9,511 | | | ||||||||||||||||||||
| Benefit Total | | | | 535,835 | | | | | 773,320 | | | ||||||||||||||||||||
Elliot Norry | | | Lump Sum Cash Severance Payment | | | | 334,766 | | | | | 446,355 | | | | | Lump Sum Cash Severance Payment | | | | 334,766 | | | | | 446,355 | | | ||||
| Lump Sum Bonus Payment(2) | | | | 60,258 | | | | | 60,258 | | | | Lump Sum Bonus Payment(2) | | | | 190,817 | | | | | 190,817 | | | |||||||
| Vesting Acceleration(3) | | | | — | | | | | 177,867 | | | | Vesting Acceleration(3) | | | | — | | | | | 133,037 | | | |||||||
| Health Insurance Premiums(4) | | | | 18,621 | | | | | 24,828 | | | | Health Insurance Premiums(4) | | | | 15,854 | | | | | 21,138 | | | |||||||
| Benefit Total | | | | 413,645 | | | | | 709,308 | | | | Benefit Total | | | | 541,437 | | | | | 791,347 | | | |||||||
Cintia Piccina | | | Lump Sum Cash Severance Payment | | | | 333,750 | | | | | 445,000 | | | ||||||||||||||||||
| Lump Sum Bonus Payment(2) | | | | 55,069 | | | | | 55,069 | | | ||||||||||||||||||||
| Vesting Acceleration(3) | | | | — | | | | | 182,609 | | | ||||||||||||||||||||
| Health Insurance Premiums(4) | | | | 12,680 | | | | | 16,906 | | | ||||||||||||||||||||
| Benefit Total | | | | 401,499 | | | | | 699,584 | | |
| PEO 2022 Compensation | | | $ | 3,364,882 | | | PEO 2023 Compensation | | | $ | 2,736,663 | | | ||
| Median Employee 2022 Compensation | | | $ | 122,820 | | | Median Employee 2023 Compensation | | | $ | 116,446 | | | ||
| Ratio of PEO to Median Employee Compensation | | | | 27:1 | | | Ratio of PEO to Median Employee Compensation | | | | 24:1 | | |
| | | Summary Compensation Table Total for CEO(1)(2) $ | | Compensation Actually Paid to CEO(3)(4) $ | | Average Summary Compensation Table Total for Non-CEO NEOs(2)(5) $ | | Average Compensation Actually Paid to Non-CEO NEOs(3)(4)(5) $ | | | Year-end value of td00 invested on December 31, 2019 in: | | | Net Income (in millions) $ | | | | Summary Compensation Table Total for PEO(2) $ | | Compensation Actually Paid to PEO(3)(5) $ | | Average Summary Compensation Table Total for non-PEO NEOs(2)(6) $ | | Average Compensation Actually Paid to non- PEO NEOs(3)(5) $ | | | Year-end value of td00 invested on December 31, 2019 in: | | | Net Income (in millions) $ | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Year | | ADAP $ | | Peer Group(6) $ | | | ADAP Total Shareholder Return $ | | Peer Group Total Shareholder Return(4) $ | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2023 | | | | 2,774,041 | | | | | 1,170,874 | | | | | 1,187,665 | | | | | 678,684 | | | | | 66.08 | | | | | 115.42 | | | | | (113.9) | | | ||||||||||||||||||||||||||||||||||||||||||||||||||
2022 | | | | 3,408,527 | | | | | 269,416 | | | | | 1,666,827 | | | | | 595,706 | | | | | 121.67 | | | | | 111.27 | | | | | -165.5 | | | | | | 3,408,527 | | | | | (47,045) | | | | | 1,666,827 | | | | | 554,575 | | | | | 121.67 | | | | | 111.27 | | | | | (165.5) | | | ||||||||||||||
2021 | | | | 4,215,001 | | | | | 2,314,854 | | | | | 1,763,728 | | | | | 906,184 | | | | | 312.50 | | | | | 124.89 | | | | | -158.1 | | | | | | 4,215,001 | | | | | 2,010,069 | | | | | 1,751,548 | | | | | 865,407 | | | | | 312.50 | | | | | 124.89 | | | | | (158.1) | | | ||||||||||||||
2020 | | | | 2,701,602 | | | | | 6,106,998 | | | | | 1,224,338 | | | | | 1,872,014 | | | | | 449.17 | | | | | 125.69 | | | | | -130.1 | | | | | | 2,701,602 | | | | | 5,925,647 | | | | | 1,276,963 | | | | | 2,547,100 | | | | | 449.17 | | | | | 125.69 | | | | | (130.1) | | |
| | | 2022 | | | 2021 | | | 2020 | | |||||||||||||||||||||||||||
| | | CEO ($) | | | Average of Other Non-CEO NEOs ($) | | | CEO ($) | | | Average of Other Non-CEO NEOs ($) | | | CEO ($) | | | Average of Other Non-CEO NEOs ($) | | ||||||||||||||||||
Total Compensation from SCT | | | | | 3,408,527 | | | | | | 1,666,827 | | | | | | 4,215,001 | | | | | | 1,763,728 | | | | | | 2,701,602 | | | | | | 1,224,338 | | |
Subtractions: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
SCT Value of Stock and Option Awards | | | | | 2,714,882 | | | | | | 1,109,700 | | | | | | 3,207,291 | | | | | | 1,069,101 | | | | | | 1,715,346 | | | | | | 676,398 | | |
Adjustments: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Addition: Fair value at year-end of awards granted during the covered fiscal year that are outstanding and unvested at year-end | | | | | 1,012,862 | | | | | | 431,655 | | | | | | 1,845,167 | | | | | | 410,038 | | | | | | 2,245,618 | | | | | | 874,484 | | |
| | | 2022 | | | 2021 | | | 2020 | | |||||||||||||||||||||||||||
| | | CEO ($) | | | Average of Other Non-CEO NEOs ($) | | | CEO ($) | | | Average of Other Non-CEO NEOs ($) | | | CEO ($) | | | Average of Other Non-CEO NEOs ($) | | ||||||||||||||||||
Addition: Fair value at vest date of awards granted and vested during the covered fiscal year | | | | | 0 | | | | | | 14,534 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Addition (Subtraction): Year-over-year change in fair value of awards granted in any prior fiscal year that are outstanding and unvested at year end | | | | | (1,154,954) | | | | | | (331,859) | | | | | | (754,546) | | | | | | (274,955) | | | | | | 1,374,067 | | | | | | 173,336 | | |
Addition (Subtraction): Change as of the vesting date (from the end of the prior fiscal year) in fair value of awards granted in any prior fiscal year for which vesting conditions were satisfied at the end of or during the covered fiscal year | | | | | (282,317) | | | | | | (75,751) | | | | | | 216,523 | | | | | | 76,474 | | | | | | 1,501,056 | | | | | | 276,254 | | |
(Subtraction): Fair value at end of prior year of awards granted in any prior fiscal year that fail to meet the applicable vesting conditions during the covered fiscal year | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Total Adjustments for Equity Awards | | | | | (3,139,111) | | | | | | (1,071,120) | | | | | | (1,900,147) | | | | | | (857,544) | | | | | | 3,405,396 | | | | | | 647,676 | | |
Compensation Actually Paid (as calculated) | | | | | 269,416 | | | | | | 595,706 | | | | | | 2,314,854 | | | | | | 906,184 | | | | | | 6,106,998 | | | | | | 1,872,014 | | |
Award Type Vesting | | | Weighted Average Fair Value | | |||||||||||||||
| 2022 | | | 2021 | | | 2020 | | |||||||||||
RSU-style options | | | | $ | 0.31 | | | | | $ | 0.53 | | | | | $ | 0.56 | | |
| | | 2023 | | | 2022 | | | 2021 | | | 2020 | | ||||||||||||
| | | PEO ($) | | | PEO ($) | | | PEO ($) | | | PEO ($) | | ||||||||||||
Total Compensation from SCT | | | | | 2,774,041 | | | | | | 3,408,527 | | | | | | 4,215,001 | | | | | | 2,701,602 | | |
Adjustments for Equity Awards: | | | | | | | | | | | | | | | | | | | | | | | | | |
Subtraction: Value of “Option Awards” reported in SCT | | | | | (1,716,163) | | | | | | (2,714,882) | | | | | | (3,207,291) | | | | | | (1,715,346) | | |
Addition: Year-end fair value of equity awards granted during the covered fiscal year that were outstanding and unvested at the covered fiscal year end | | | | | 657,969 | | | | | | 1,013,706 | | | | | | 1,885,426 | | | | | | 2,294,274 | | |
| | | For Stock Options Vesting in | | ||||||
| | | 2022 | | | 2021 | | | 2020 | |
Expected volatility | | | 104% – 117% | | | 103% – 119% | | | 74% – 118% | |
Expected dividend yield | | | 0% | | | 0% | | | 0% | |
Expected life, in years | | | 3.0 – 4.5 | | | 3.0 – 4.5 | | | 3.0 – 4.5 | |
Risk-free interest rate | | | 1.0% – 4.6% | | | 0.2% – 1.3% | | | 0.1% – 1.7% | |
| | | 2023 | | | 2022 | | | 2021 | | | 2020 | | ||||||||||||
| | | PEO ($) | | | PEO ($) | | | PEO ($) | | | PEO ($) | | ||||||||||||
Addition (Subtraction): Year-over-year change in fair value at covered fiscal year end of equity awards granted in prior fiscal years that were outstanding and unvested at the covered fiscal year end | | | | | (465,401) | | | | | | (1,186,052) | | | | | | (776,601) | | | | | | 1,404,606 | | |
Addition: Fair value at vest date for awards granted and vested during the covered fiscal year | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Addition (Subtraction): Change as of the vesting date (from the end of the prior fiscal year) in fair value of equity awards granted in prior fiscal years that vested in the covered fiscal year | | | | | (79,572) | | | | | | (568,344) | | | | | | (106,467) | | | | | | 1,240,510 | | |
(Subtraction): Fair value at end of prior fiscal year of awards granted in any prior fiscal year that fail to meet the applicable vesting conditions during the covered fiscal year | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Compensation Actually Paid (as calculated) | | | | | 1,170,874 | | | | | | (47,045) | | | | | | 2,010,069 | | | | | | 5,925,647 | | |
| | | 2023 | | | 2022 | | | 2021 | | | 2020 | | ||||||||||||
| | | Average of Other non- PEO NEOs ($) | | | Average of Other non- PEO NEOs ($) | | | Average of Other non- PEO NEOs ($) | | | Average of Other non- PEO NEOs ($) | | ||||||||||||
Total Compensation from SCT | | | | | 1,187,665 | | | | | | 1,666,827 | | | | | | 1,751,548 | | | | | | 1,276,963 | | |
Adjustments for Equity Awards: | | | | | | | | | | | | | | | | | | | | | | | | | |
Subtraction: Value of “Option Awards” reported in SCT | | | | | (505,845) | | | | | | (1,109,700) | | | | | | (1,069,101) | | | | | | (712,650) | | |
Addition: Year-end fair value of equity awards granted during the covered fiscal year that were outstanding and unvested at the covered fiscal year end | | | | | 193,626 | | | | | | 457,510 | | | | | | 628,477 | | | | | | 1,171,315 | | |
Addition (Subtraction): Year-over-year change in fair value at covered fiscal year end of equity awards granted in prior fiscal years that were outstanding and unvested at the covered fiscal year end | | | | | (166,364) | | | | | | (340,406) | | | | | | (396,948) | | | | | | 400,307 | | |
Addition: Fair value at vest date for awards granted and vested during the covered fiscal year | | | | | 0 | | | | | | 25,837 | | | | | | 0 | | | | | | 0 | | |
Addition (Subtraction): Change as of the vesting date (from the end of the prior fiscal year) in fair value of equity awards granted in prior fiscal years that vested in the covered fiscal year | | | | | (30,397) | | | | | | (145,493) | | | | | | (48,569) | | | | | | 411,165 | | |
| | | 2023 | | | 2022 | | | 2021 | | | 2020 | | ||||||||||||
| | | Average of Other non- PEO NEOs ($) | | | Average of Other non- PEO NEOs ($) | | | Average of Other non- PEO NEOs ($) | | | Average of Other non- PEO NEOs ($) | | ||||||||||||
(Subtraction): Fair value at end of prior fiscal year of awards granted in any prior fiscal year that fail to meet the applicable vesting conditions during the covered fiscal year | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Compensation Actually Paid (as calculated) | | | | | 678,684 | | | | | | 554,575 | | | | | | 865,407 | | | | | | 2,547,100 | | |
Award Type Vesting | | | Weighted Average Fair Value | | |||||||||||||||||||||
| 2023 | | | 2022 | | | 2021 | | | 2020 | | ||||||||||||||
RSU-style options | | | | $ | 0.29 | | | | | $ | 0.48 | | | | | $ | 0.92 | | | | | $ | 0.62 | | |
| | | For Stock Options Vesting in | | |||||||||
| | | 2023 | | | 2022 | | | 2021 | | | 2020 | |
Expected volatility | | | 77% – 116% | | | 104% – 117% | | | 103% – 119% | | | 74% – 118% | |
Expected dividend yield | | | 0% | | | 0% | | | 0% | | | 0% | |
Expected life, in years | | | 3.0 – 4.5 | | | 3.0 – 4.5 | | | 3.0 – 4.5 | | | 3.0 – 4.5 | |
Risk-free interest rate | | | 3.5% – 4.9% | | | 1.0% – 4.6% | | | 0.2% – 1.3% | | | 0.1% – 1.7% | |
Plan Category | | Number of Securities to be Issued Upon Exercise of Outstanding Options | | Weighted Average Exercise Price of Outstanding Options $ | | Number of Securities Available for Future Issuance Under Equity Compensation Plans | | | Number of Securities to be Issued Upon Exercise of Outstanding Options | | Weighted Average Exercise Price of Outstanding Options $ | | Number of Securities Available for Future Issuance Under Equity Compensation Plans | | ||||||||||||||||||||||||
Equity compensation plans | | | | 152,539,089 | | | | | 0.53 | | | | | 77,452,163 | | | | | | 191,150,175 | | | | | 0.52 | | | | | 77,023,185 | | | ||||||
Total | | | | 152,539,089 | | | | | 0.53 | | | | | 77,452,163 | | | | | | 191,150,175 | | | | | 0.52 | | | | | 77,023,185 | | |
| | | For the year ended 31 December 2022: | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | Fixed Pay(1) | | | Variable Pay(1) | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||
Name of Director | | | Salary and fees $ | | | Benefits $ | | | Pension allowance $ | | | Total fixed $ | | | Annual bonus $ | | | Equity- Based Awards (6) $ | | | Total variable $ | | | Overall Total $ | | | Fixed pay % | | | Variable pay % | | ||||||||||||||||||||||||||||||
Executive | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Adrian Rawcliffe (CEO) | | | | | 650,000(2) | | | | | | 27,028(3) | | | | | | 16,617(4) | | | | | | 693,645 | | | | | | —(5) | | | | | | 627,022 | | | | | | 627,022 | | | | | | 1,320,667 | | | | | | 52.52% | | | | | | 47.48% | | |
Non-executives | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
David Mott (Chairman) | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0% | | | | | | 0% | | |
Lawrence Alleva | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0% | | | | | | 0% | | |
Ali Behbahani | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0% | | | | | | 0% | | |
Barbara Duncan | | | | | 50,000 | | | | | | — | | | | | | — | | | | | | 50,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | 50,000 | | | | | | 100% | | | | | | 0% | | |
John Furey | | | | | 57,500 | | | | | | — | | | | | | — | | | | | | 57,500 | | | | | | — | | | | | | — | | | | | | — | | | | | | 57,500 | | | | | | 100% | | | | | | 0% | | |
James Noble | | | | | 17,532(2) | | | | | | — | | | | | | — | | | | | | 17,532 | | | | | | — | | | | | | — | | | | | | — | | | | | | 17,532 | | | | | | 100% | | | | | | 0% | | |
Elliott Sigal | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0% | | | | | | 0% | | |
Tal Zaks | | | | | 47,500 | | | | | | — | | | | | | — | | | | | | 47,500 | | | | | | — | | | | | | — | | | | | | — | | | | | | 47,500 | | | | | | 100% | | | | | | 0% | | |
| | | For the year ended 31 December 2021: | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | Fixed Pay(1) | | | Variable Pay(1) | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||
Name of Director | | | Salary and fees $ | | | Benefits $ | | | Pension allowance $ | | | Total fixed $ | | | Annual bonus $(6) | | | Equity- Based Awards $ | | | Total variable $ | | | Overall Total $ | | | Fixed pay % | | | Variable pay % | | ||||||||||||||||||||||||||||||
Executive | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Adrian Rawcliffe (CEO) | | | | | 617,050(2) | | | | | | 24,941(3) | | | | | | 14,000(4) | | | | | | 655,991 | | | | | | 351,719(5) | | | | | | 748,985 | | | | | | 1,100,704 | | | | | | 1,756,695 | | | | | | 37.34% | | | | | | 62.66% | | |
Non-executives | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
David Mott (Chairman) | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0% | | | | | | 0% | | |
Lawrence Alleva | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0% | | | | | | 0% | | |
Ali Behbahani | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0% | | | | | | 0% | | |
Barbara Duncan | | | | | 50,000 | | | | | | — | | | | | | — | | | | | | 50,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | 50,000 | | | | | | 100% | | | | | | 0% | | |
John Furey | | | | | 28,750(2) | | | | | | — | | | | | | — | | | | | | 28,750 | | | | | | — | | | | | | — | | | | | | — | | | | | | 28,750 | | | | | | 100% | | | | | | 0% | | |
James Noble | | | | | 17,532(2) | | | | | | — | | | | | | — | | | | | | 17,532 | | | | | | — | | | | | | — | | | | | | — | | | | | | 17,532 | | | | | | 100% | | | | | | 0% | | |
Elliott Sigal | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0% | | | | | | 0% | | |
Tal Zaks | | | | | 47,500 | | | | | | — | | | | | | — | | | | | | 47,500 | | | | | | — | | | | | | — | | | | | | — | | | | | | 47,500 | | | | | | 100% | | | | | | 0% | | |
| | | For the year ended 31 December 2023: | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | Fixed Pay(1) | | | Variable Pay(1) | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||
Name of Director | | | Salary and fees $ | | | Benefits $ | | | Pension allowance $ | | | Total fixed $ | | | Annual bonus $ | | | Equity- Based Awards(6) $ | | | Total variable $ | | | Overall Total $ | | | Fixed pay % | | | Variable pay % | | ||||||||||||||||||||||||||||||
Executive | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Adrian Rawcliffe (CEO) | | | | | 650,000(2) | | | | | | 22,128(3) | | | | | | 15,250(4) | | | | | | 687,378 | | | | | | 370,500(5) | | | | | | 555,306 | | | | | | 925,806 | | | | | | 1,613,184 | | | | | | 42.61% | | | | | | 57.39% | | |
Non-executives | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
David Mott (Chairman) | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0% | | | | | | 0% | | |
Andrew Allen | | | | | 23,750(2) | | | | | | — | | | | | | — | | | | | | 23,750 | | | | | | — | | | | | | — | | | | | | — | | | | | | 23,750 | | | | | | 100% | | | | | | 0% | | |
Lawrence Alleva | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0% | | | | | | 0% | | |
Ali Behbahani | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0% | | | | | | 0% | | |
Barbara Duncan | | | | | 20,833(2) | | | | | | — | | | | | | — | | | | | | 20,833 | | | | | | — | | | | | | — | | | | | | — | | | | | | 20,833 | | | | | | 100% | | | | | | 0% | | |
John Furey | | | | | 57,500 | | | | | | — | | | | | | — | | | | | | 57,500 | | | | | | — | | | | | | — | | | | | | — | | | | | | 57,500 | | | | | | 100% | | | | | | 0% | | |
Priti Hegde | | | | | 22,500(2) | | | | | | — | | | | | | — | | | | | | 22,500 | | | | | | — | | | | | | — | | | | | | — | | | | | | 22,500 | | | | | | 100% | | | | | | 0% | | |
Kristen Hege | | | | | 6,667(2) | | | | | | — | | | | | | — | | | | | | 6,667 | | | | | | — | | | | | | — | | | | | | — | | | | | | 6,667 | | | | | | 100% | | | | | | 0% | | |
Garry Menzel | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0% | | | | | | 0% | | |
James Noble | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0% | | | | | | 0% | | |
Elliott Sigal | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0% | | | | | | 0% | | |
Tal Zaks | | | | | 11,875(2) | | | | | | — | | | | | | — | | | | | | 11,875 | | | | | | — | | | | | | — | | | | | | — | | | | | | 11,875 | | | | | | 100% | | | | | | 0% | | |
| | | For the year ended 31 December 2022: | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | Fixed Pay(1) | | | Variable Pay(1) | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||
Name of Director | | | Salary and fees $ | | | Benefits $ | | | Pension allowance $ | | | Total fixed $ | | | Annual bonus $ | | | Equity- Based Awards(6) $ | | | Total variable $ | | | Overall Total $ | | | Fixed pay % | | | Variable pay % | | ||||||||||||||||||||||||||||||
Executive | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Adrian Rawcliffe (CEO) | | | | | 650,000(2) | | | | | | 27,028(3) | | | | | | 16,617(4) | | | | | | 693,645 | | | | | | —(5) | | | | | | 627,022 | | | | | | 627,022 | | | | | | 1,320,667 | | | | | | 52.52% | | | | | | 47.48% | | |
Non-executives | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
David Mott (Chairman) | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0% | | | | | | 0% | | |
Lawrence Alleva | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0% | | | | | | 0% | | |
Ali Behbahani | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0% | | | | | | 0% | | |
Barbara Duncan | | | | | 50,000 | | | | | | — | | | | | | — | | | | | | 50,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | 50,000 | | | | | | 100% | | | | | | 0% | | |
John Furey | | | | | 57,500 | | | | | | — | | | | | | — | | | | | | 57,500 | | | | | | — | | | | | | — | | | | | | — | | | | | | 57,500 | | | | | | 100% | | | | | | 0% | | |
| | | For the year ended 31 December 2022: | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | Fixed Pay(1) | | | Variable Pay(1) | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||
Name of Director | | | Salary and fees $ | | | Benefits $ | | | Pension allowance $ | | | Total fixed $ | | | Annual bonus $ | | | Equity- Based Awards(6) $ | | | Total variable $ | | | Overall Total $ | | | Fixed pay % | | | Variable pay % | | ||||||||||||||||||||||||||||||
James Noble | | | | | 18,443(2) | | | | | | — | | | | | | — | | | | | | 18,443 | | | | | | — | | | | | | — | | | | | | — | | | | | | 18,443 | | | | | | 100% | | | | | | 0% | | |
Elliott Sigal | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0% | | | | | | 0% | | |
Tal Zaks | | | | | 47,500 | | | | | | — | | | | | | — | | | | | | 47,500 | | | | | | — | | | | | | — | | | | | | — | | | | | | 47,500 | | | | | | 100% | | | | | | 0% | | |
Name of Director | | | Shares owned | | | Total share options | | | Vested share options(1) | | | Options exercised during year ended 31 December 2022 | | ||||||||||||
Executive Director | | | | | | | | | | | | | | | | | | | | | | | | | |
Adrian Rawcliffe (CEO) | | | | | 557,646(2) | | | | | | 21,697,500 | | | | | | 12,390,162 | | | | | | 501,348 | | |
Non-Executive Directors | | | | | | | | | | | | | | | | | | | | | | | | | |
David Mott (Chairman) | | | | | — | | | | | | 3,002,163 | | | | | | 2,001,724 | | | | | | — | | |
Lawrence Alleva | | | | | 143,364(3) | | | | | | 2,905,500 | | | | | | 2,089,433 | | | | | | — | | |
Ali Behbahani | | | | | — | | | | | | 2,345,941 | | | | | | 1,608,891 | | | | | | — | | |
Barbara Duncan | | | | | — | | | | | | 1,867,562 | | | | | | 1,367,562 | | | | | | — | | |
John Furey | | | | | — | | | | | | 1,600,748 | | | | | | 1,100,748 | | | | | | — | | |
James Noble | | | | | 8,145,700 | | | | | | 10,408,244 | | | | | | 9,697,533 | | | | | | — | | |
Elliott Sigal | | | | | 367,038(4) | | | | | | 2,734,336 | | | | | | 1,997,286 | | | | | | — | | |
Tal Zaks | | | | | — | | | | | | 1,703,788 | | | | | | 1,203,788 | | | | | | — | | |
Name of Director | | | Shares owned | | | Total share options | | | Vested share options(1) | | | Options exercised during year ended 31 December 2023 | | ||||||||||||
Executive Director | | | | | | | | | | | | | | | | | | | | | | | | | |
Adrian Rawcliffe (CEO) | | | | | 972,426(2) | | | | | | 27,461,190 | | | | | | 16,304,266 | | | | | | 724,806 | | |
Non-Executive Directors | | | | | | | | | | | | | | | | | | | | | | | | | |
David Mott (Chairman) | | | | | — | | | | | | 4,465,090 | | | | | | 3,002,163 | | | | | | — | | |
Andrew Allen | | | | | — | | | | | | 1,047,296 | | | | | | 357,750 | | | | | | — | | |
Lawrence Alleva | | | | | 143,364(3) | | | | | | 3,983,256 | | | | | | 2,905,500 | | | | | | — | | |
Ali Behbahani | | | | | — | | | | | | 3,279,258 | | | | | | 2,345,941 | | | | | | — | | |
Barbara Duncan | | | | | — | | | | | | 1,867,562 | | | | | | 1,867,562 | | | | | | — | | |
John Furey | | | | | — | | | | | | 2,100,748 | | | | | | 1,600,748 | | | | | | — | | |
Priti Hegde | | | | | — | | | | | | 988,586 | | | | | | 273,098 | | | | | | — | | |
Kristen Hege | | | | | — | | | | | | 1,000,000 | | | | | | — | | | | | | — | | |
Garry Menzel | | | | | 4,117,680(4) | | | | | | 11,093,593 | | | | | | 10,112,130 | | | | | | 736,548 | | |
James Noble | | | | | 8,145,700 | | | | | | 10,408,244 | | | | | | 10,408,244 | | | | | | — | | |
Elliott Sigal | | | | | 314,100(5) | | | | | | 3,667,653 | | | | | | 3,667,653 | | | | | | — | | |
Tal Zaks | | | | | — | | | | | | 1,703,788 | | | | | | 1,703,788 | | | | | | — | | |
Name of Director | | | Options Held | | | Grant date | | | Start date for vesting | | | Exercise price | | | First date of exercise of some or all options(1) | | | Date of expiry | | ||||||||||||||||||
Executive Director | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Adrian Rawcliffe (CEO) | | | | | 3,000,000 | | | | | | 16/03/15 | | | | | | 16/03/15 | | | | | £ | 0.50 | | | | | | 16/03/16 | | | | | | 16/03/25 | | |
| | | | | 939,948 | | | | | | 18/01/16 | | | | | | 18/01/16 | | | | | £ | 0.89 | | | | | | 18/01/17 | | | | | | 18/01/26 | | |
| | | | | 2,072,976 | | | | | | 13/01/17 | | | | | | 13/01/17 | | | | | £ | 0.59 | | | | | | 13/01/18 | | | | | | 13/01/27 | | |
| | | | | 687,984 | | | | | | 12/01/18 | | | | | | 12/01/18 | | | | | £ | 0.96 | | | | | | 12/01/19 | | | | | | 12/01/28 | | |
| | | | | 70,224 | | | | | | 04/01/19 | | | | | | 04/01/19 | | | | | £ | 0.001 | | | | | | 04/01/20 | | | | | | 04/01/29 | | |
| | | | | 1,257,744 | | | | | | 04/01/19 | | | | | | 04/01/19 | | | | | £ | 0.70 | | | | | | 04/01/20 | | | | | | 04/01/29 | | |
| | | | | 35,112 | | | | | | 27/06/19 | | | | | | 27/06/19 | | | | | £ | 0.001 | | | | | | 27/06/20 | | | | | | 27/06/29 | | |
| | | | | 628,872 | | | | | | 27/06/19 | | | | | | 27/06/19 | | | | | £ | 0.53 | | | | | | 27/06/20 | | | | | | 27/06/29 | | |
| | | | | 35,112 | | | | | | 01/09/19 | | | | | | 01/09/19 | | | | | £ | 0.001 | | | | | | 01/09/20 | | | | | | 01/09/29 | | |
| | | | | 628,872 | | | | | | 01/09/19 | | | | | | 01/09/19 | | | | | £ | 0.22 | | | | | | 01/09/20 | | | | | | 01/09/29 | | |
| | | | | 2,515,536 | | | | | | 16/01/20 | | | | | | 16/01/20 | | | | | £ | 0.57 | | | | | | 16/01/21 | | | | | | 16/01/30 | | |
| | | | | 280,896 | | | | | | 16/01/20 | | | | | | 16/01/20 | | | | | £ | 0.001 | | | | | | 16/01/21 | | | | | | 16/01/30 | | |
| | | | | 546,120 | | | | | | 11/01/21 | | | | | | 11/01/2021 | | | | | £ | 0.001 | | | | | | 11/01/22 | | | | | | 11/01/31 | | |
| | | | | 3,260,400 | | | | | | 11/01/21 | | | | | | 11/01/2021 | | | | | £ | 0.76 | | | | | | 11/01/22 | | | | | | 11/01/31 | | |
| | | | | 1,047,480 | | | | | | 12/01/22 | | | | | | 12/01/2022 | | | | | £ | 0.001 | | | | | | 12/01/23 | | | | | | 12/01/32 | | |
| | | | | 4,690,224 | | | | | | 12/01/22 | | | | | | 12/01/2022 | | | | | £ | 0.44 | | | | | | 12/01/23 | | | | | | 12/01/32 | | |
Total | | | | | 21,697,500 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Non-Executive Directors | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
David Mott (Chairman) | | | | | 163,229 | | | | | | 11/05/15 | | | | | | 11/05/15 | | | | | £ | 1.82 | | | | | | 11/05/15 | | | | | | 11/05/25 | | |
| | | | | 191,410 | | | | | | 11/08/16 | | | | | | 11/08/16 | | | | | £ | 0.97 | | | | | | 11/08/17 | | | | | | 11/08/26 | | |
| | | | | 302,561 | | | | | | 03/07/17 | | | | | | 03/07/17 | | | | | £ | 0.58 | | | | | | 03/07/18 | | | | | | 03/07/27 | | |
| | | | | 187,330 | | | | | | 22/06/18 | | | | | | 22/06/18 | | | | | £ | 1.65 | | | | | | 22/06/19 | | | | | | 22/06/28 | | |
Name of Director | | Options Held | | Grant date | | Start date for vesting | | Exercise price | | First date of exercise of some or all options(1) | | Date of expiry | | | Options Held | | Grant date | | Start date for vesting | | Exercise price | | First date of exercise of some or all options(1) | | Date of expiry | | ||||||||||||||||||||||||||||||||||||
Executive Director | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
Adrian Rawcliffe (CEO) | | | | 3,000,000 | | | 16/03/15 | | 16/03/15 | | | £ | 0.50 | | | 16/03/16 | | 16/03/25 | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 350,947 | | | | | 02/07/19 | | | | | 02/07/19 | | | | £ | 0.48 | | | | | 02/07/20 | | | | | 02/07/29 | | | | | | 939,948 | | | 18/01/16 | | 18/01/16 | | | £ | 0.89 | | | 18/01/17 | | 18/01/26 | | ||||||||||||
| | | | 226,753 | | | | | 01/07/20 | | | | | 01/07/20 | | | | £ | 1.35 | | | | | 01/07/21 | | | | | 01/07/30 | | | | | | 2,072,976 | | | 13/01/17 | | 13/01/17 | | | £ | 0.59 | | | 13/01/18 | | 13/01/27 | | ||||||||||||
| | | | 579,494 | | | | | 01/07/21 | | | | | 01/07/21 | | | | £ | 0.51 | | | | | 01/07/22 | | | | | 01/07/31 | | | | | | 687,984 | | | 12/01/18 | | 12/01/18 | | | £ | 0.96 | | | 12/01/19 | | 12/01/28 | | ||||||||||||
| | | | 1,000,439 | | | | | 01/07/22 | | | | | 01/07/22 | | | | £ | 0.23 | | | | | 01/07/23 | | | | | 01/07/32 | | | | | | 1,257,744 | | | 04/01/19 | | 04/01/19 | | | £ | 0.70 | | | 04/01/20 | | 04/01/29 | | ||||||||||||
Total | | | | 3,002,163 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||
Lawrence Alleva(2) | | | | 519,481 | | | | | 16/03/15 | | | | | 16/03/15 | | | | £ | 0.50 | | | | | 16/03/16 | | | | | 16/03/25 | | | |||||||||||||||||||||||||||||||
| | | | 628,872 | | | 27/06/19 | | 27/06/19 | | | £ | 0.53 | | | 27/06/20 | | 27/06/29 | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 628,872 | | | 01/09/19 | | 01/09/19 | | | £ | 0.22 | | | 01/09/20 | | 01/09/29 | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 30,745 | | | | | 11/05/15 | | | | | 11/05/15 | | | | £ | 1.82 | | | | | 11/05/15 | | | | | 11/05/25 | | | | | | 2,515,536 | | | 16/01/20 | | 16/01/20 | | | £ | 0.57 | | | 16/01/21 | | 16/01/30 | | ||||||||||||
| | | | 196,678 | | | | | 11/08/16 | | | | | 11/08/16 | | | | £ | 0.97 | | | | | 11/08/17 | | | | | 11/08/26 | | | | | | 140,448 | | | 16/01/20 | | 16/01/20 | | | £ | 0.001 | | | 16/01/21 | | 16/01/30 | | ||||||||||||
| | | | 243,724 | | | | | 03/07/17 | | | | | 03/07/17 | | | | £ | 0.58 | | | | | 03/07/18 | | | | | 03/07/27 | | | | | | 364,080 | | | 11/01/21 | | 11/01/2021 | | | £ | 0.001 | | | 11/01/22 | | 11/01/31 | | ||||||||||||
| | | | 124,000 | | | | | 22/06/18 | | | | | 22/06/18 | | | | £ | 1.65 | | | | | 22/06/19 | | | | | 22/06/28 | | | | | | 3,260,400 | | | 11/01/21 | | 11/01/2021 | | | £ | 0.76 | | | 11/01/22 | | 11/01/31 | | ||||||||||||
| | | | 271,209 | | | | | 02/07/19 | | | | | 02/07/19 | | | | £ | 0.48 | | | | �� | 02/07/20 | | | | | 02/07/29 | | | | | | 785,610 | | | 12/01/22 | | 12/01/2022 | | | £ | 0.001 | | | 12/01/23 | | 12/01/32 | | ||||||||||||
| | | | 197,678 | | | | | 01/07/20 | | | | | 01/07/20 | | | | £ | 1.35 | | | | | 01/07/21 | | | | | 01/07/30 | | | | | | 4,690,224 | | | 12/01/22 | | 12/01/2022 | | | £ | 0.44 | | | 12/01/23 | | 12/01/32 | | ||||||||||||
| | | | 505,918 | | | | | 01/07/21 | | | | | 01/07/21 | | | | £ | 0.51 | | | | | 01/07/22 | | | | | 01/07/31 | | | | | | 1,798,272 | | | 17/01/23 | | 17/01/23 | | | £ | 0.001 | | | 17/01/24 | | 17/01/33 | | ||||||||||||
| | | | 816,067 | | | | | 01/07/22 | | | | | 01/07/22 | | | | £ | 0.23 | | | | | 01/07/23 | | | | | 01/07/32 | | | | | | 4,690,224 | | | 17/01/23 | | 17/01/23 | | | £ | 0.26 | | | 17/01/24 | | 17/01/33 | | ||||||||||||
Total | | | | 2,905,500 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 27,461,190 | | | | | | | | | | | | | | | | ||||||||||||
Ali Behbahani | | | | 155,682 | | | | | 11/05/15 | | | | | 11/05/15 | | | | £ | 1.82 | | | | | 11/05/15 | | | | | 11/05/25 | | | |||||||||||||||||||||||||||||||
Non-Executive Directors | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
David Mott (Chairman) | | | | 163,229 | | | 11/05/15 | | 11/05/15 | | | £ | 1.82 | | | 11/05/15 | | 11/05/25 | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 191,410 | | | 11/08/16 | | 11/08/16 | | | £ | 0.97 | | | 11/08/17 | | 11/08/26 | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 184,562 | | | | | 11/08/16 | | | | | 11/08/16 | | | | £ | 0.97 | | | | | 11/08/17 | | | | | 11/08/26 | | | | | | 302,561 | | | 03/07/17 | | 03/07/17 | | | £ | 0.58 | | | 03/07/18 | | 03/07/27 | | ||||||||||||
| | | | 220,788 | | | | | 03/07/17 | | | | | 03/07/17 | | | | £ | 0.58 | | | | | 03/07/18 | | | | | 03/07/27 | | | | | | 187,330 | | | 22/06/18 | | 22/06/18 | | | £ | 1.65 | | | 22/06/19 | | 22/06/28 | | ||||||||||||
| | | | 154,809 | | | | | 22/06/18 | | | | | 22/06/18 | | | | £ | 1.65 | | | | | 22/06/19 | | | | | 22/06/28 | | | | | | 350,947 | | | 02/07/19 | | 02/07/19 | | | £ | 0.48 | | | 02/07/20 | | 02/07/29 | | ||||||||||||
| | | | 234,407 | | | | | 02/07/19 | | | | | 02/07/19 | | | | £ | 0.48 | | | | | 02/07/20 | | | | | 02/07/29 | | | | | | 226,753 | | | 01/07/20 | | 01/07/20 | | | £ | 1.35 | | | 01/07/21 | | 01/07/30 | | ||||||||||||
| | | | 184,258 | | | | | 01/07/20 | | | | | 01/07/20 | | | | £ | 1.35 | | | | | 01/07/21 | | | | | 01/07/30 | | | | | | 579,494 | | | 01/07/21 | | 01/07/21 | | | £ | 0.51 | | | 01/07/22 | | 01/07/31 | | ||||||||||||
| | | | 474,385 | | | | | 01/07/21 | | | | | 01/07/21 | | | | £ | 0.51 | | | | | 01/07/22 | | | | | 01/07/31 | | | | | | 1,000,439 | | | 01/07/22 | | 01/07/22 | | | £ | 0.23 | | | 01/07/23 | | 01/07/32 | | ||||||||||||
| | | | 737,050 | | | | | 01/07/22 | | | | | 01/07/22 | | | | £ | 0.23 | | | | | 01/07/23 | | | | | 01/07/32 | | | | | | 1,462,927 | | | 03/07/23 | | 03/07/23 | | | £ | 0.12 | | | 03/07/24 | | 03/07/33 | | ||||||||||||
Total | | | | 2,345,941 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 4,465,090 | | | | | | | | | | | | | | | | ||||||||||||
Barbara Duncan(3) | | | | 332,776 | | | | | 23/06/16 | | | | | 23/06/16 | | | | £ | 1.01 | | | | | 23/06/17 | | | | | 23/06/26 | | | |||||||||||||||||||||||||||||||
| | | | 228,765 | | | | | 03/07/17 | | | | | 03/07/17 | | | | £ | 0.58 | | | | | 03/07/18 | | | | | 03/07/27 | | | |||||||||||||||||||||||||||||||
| | | | 158,233 | | | | | 22/06/18 | | | | | 22/06/18 | | | | £ | 1.65 | | | | | 22/06/19 | | | | | 22/06/28 | | | |||||||||||||||||||||||||||||||
| | ��� | | | 124,000 | | | | | 02/07/19 | | | | | 02/07/19 | | | | £ | 0.48 | | | | | 02/07/20 | | | | | 02/07/29 | | | ||||||||||||||||||||||||||||||
| | | | 144,000 | | | | | 01/07/20 | | | | | 01/07/20 | | | | £ | 1.35 | | | | | 01/07/21 | | | | | 01/07/30 | | | |||||||||||||||||||||||||||||||
| | | | 379,788 | | | | | 01/07/21 | | | | | 01/07/21 | | | | £ | 0.51 | | | | | 01/07/22 | | | | | 01/07/31 | | | |||||||||||||||||||||||||||||||
| | | | 500,000 | | | | | 01/07/22 | | | | | 01/07/22 | | | | £ | 0.23 | | | | | 01/07/23 | | | | | 01/07/32 | | | |||||||||||||||||||||||||||||||
Total | | | | 1,867,562 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||
John Furey(3) | | | | 284,233 | | | | | 05/07/18 | | | | | 05/07/18 | | | | £ | 1.49 | | | | | 05/07/19 | | | | | 05/07/28 | | | |||||||||||||||||||||||||||||||
| | | | 240,541 | | | | | 02/07/19 | | | | | 02/07/19 | | | | £ | 0.48 | | | | | 02/07/20 | | | | | 02/07/29 | | | |||||||||||||||||||||||||||||||
| | | | 196,186 | | | | | 01/07/20 | | | | | 01/07/20 | | | | £ | 1.35 | | | | | 01/07/21 | | | | | 01/07/30 | | | |||||||||||||||||||||||||||||||
| | | | 379,788 | | | | | 01/07/21 | | | | | 01/07/21 | | | | £ | 0.51 | | | | | 01/07/22 | | | | | 01/07/31 | | | |||||||||||||||||||||||||||||||
| | | | 500,000 | | | | | 01/07/22 | | | | | 01/07/22 | | | | £ | 0.23 | | | | | 01/07/23 | | | | | 01/07/32 | | | |||||||||||||||||||||||||||||||
Total | | | | 1,600,748 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||
James Noble(4) | | | | 3,500,000 | | | | | 20/03/15 | | | | | 19/12/14 | | | | £ | 0.3557 | | | | | 19/12/15 | | | | | 19/12/24 | | | |||||||||||||||||||||||||||||||
| | | | 1,968,016 | | | | | 18/01/16 | | | | | 18/01/16 | | | | £ | 0.89 | | | | | 18/01/17 | | | | | 18/01/26 | | | |||||||||||||||||||||||||||||||
| | | | 1,641,106 | | | | | 13/01/17 | | | | | 13/01/17 | | | | £ | 0.59 | | | | | 13/01/18 | | | | | 13/01/27 | | | |||||||||||||||||||||||||||||||
| | | | 931,632 | | | | | 12/01/18 | | | | | 12/01/18 | | | | £ | 0.96 | | | | | 12/01/19 | | | | | 12/01/28 | | |
Name of Director | | Options Held | | Grant date | | Start date for vesting | | Exercise price | | First date of exercise of some or all options(1) | | Date of expiry | | | Options Held | | Grant date | | Start date for vesting | | Exercise price | | First date of exercise of some or all options(1) | | Date of expiry | | ||||||||||||||||||||||||||||||||||||
| | | | 192,060 | | | | | 12/01/18 | | | | | 12/01/18 | | | | £ | 0.001 | | | | | 12/01/19 | | | | | 12/01/28 | | | |||||||||||||||||||||||||||||||
Andrew Allen(2) | | | | 500,000 | | | 03/07/23 | | 03/07/23 | | | £ | 0.12 | | | 03/07/24 | | 03/07/33 | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 140,448 | | | | | 04/01/19 | | | | | 04/01/19 | | | | £ | 0.001 | | | | | 04/01/20 | | | | | 04/01/29 | | | | | | 73,212 | | | 05/07/23 | | 05/07/23 | | | £ | 0.70 | | | 05/07/23 | | 12/12/28 | | ||||||||||||
| | | | 733,698 | | | | | 04/01/19 | | | | | 04/01/19 | | | | £ | 0.70 | | | | | 04/01/20 | | | | | 04/01/29 | | | | | | 56,868 | | | 05/07/23 | | 05/07/23 | | | £ | 1.40 | | | 05/07/23 | | 10/04/29 | | ||||||||||||
| | | | 31,000 | | | | | 01/04/20 | | | | | 01/04/20 | | | | £ | 0.36 | | | | | 01/04/21 | | | | | 01/04/30 | | | | | | 45,348 | | | 05/07/23 | | 05/07/23 | | | £ | 1.40 | | | 05/07/23 | | 18/12/29 | | ||||||||||||
| | | | 179,785 | | | | | 01/07/20 | | | | | 01/07/20 | | | | £ | 1.35 | | | | | 01/07/21 | | | | | 01/07/30 | | | | | | 109,746 | | | 05/07/23 | | 05/07/23 | | | £ | 2.76 | | | 05/07/23 | | 09/12/30 | | ||||||||||||
| | | | 379,788 | | | | | 01/07/21 | | | | | 01/07/21 | | | | £ | 0.51 | | | | | 01/07/22 | | | | | 01/07/31 | | | | | | 109,746 | | | 05/07/23 | | 05/07/23 | | | £ | 0.46 | | | 05/07/23 | | 08/12/31 | | ||||||||||||
| | | | 710,711 | | | | | 01/07/22 | | | | | 01/07/22 | | | | £ | 0.23 | | | | | 01/07/23 | | | | | 01/07/32 | | | | | | 152,376 | | | 05/07/23 | | 05/07/23 | | | £ | 0.09 | | | 15/12/23 | | 14/12/32 | | ||||||||||||
Total | | | | 10,408,244 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,047,296 | | | | | | | | | | | | | | | | ||||||||||||
Elliott Sigal(2) | | | | 519,481 | | | | | 16/03/15 | | | | | 16/03/15 | | | | £ | 0.50 | | | | | 16/03/16 | | | | | 16/03/25 | | | |||||||||||||||||||||||||||||||
Lawrence Alleva(3) | | | | 519,481 | | | 16/03/15 | | 16/03/15 | | | £ | 0.50 | | | 16/03/16 | | 16/03/25 | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 30,745 | | | 11/05/15 | | 11/05/15 | | | £ | 1.82 | | | 11/05/15 | | 11/05/25 | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 24,596 | | | | | 11/05/15 | | | | | 11/05/15 | | | | £ | 1.82 | | | | | 11/05/15 | | | | | 11/05/25 | | | | | | 196,678 | | | 11/08/16 | | 11/08/16 | | | £ | 0.97 | | | 11/08/17 | | 11/08/26 | | ||||||||||||
| | | | 184,562 | | | | | 11/08/16 | | | | | 11/08/16 | | | | £ | 0.97 | | | | | 11/08/17 | | | | | 11/08/26 | | | | | | 243,724 | | | 03/07/17 | | 03/07/17 | | | £ | 0.58 | | | 03/07/18 | | 03/07/27 | | ||||||||||||
| | | | 220,788 | | | | | 03/07/17 | | | | | 03/07/17 | | | | £ | 0.58 | | | | | 03/07/18 | | | | | 03/07/27 | | | | | | 124,000 | | | 22/06/18 | | 22/06/18 | | | £ | 1.65 | | | 22/06/19 | | 22/06/28 | | ||||||||||||
| | | | 154,809 | | | | | 22/06/18 | | | | | 22/06/18 | | | | £ | 1.65 | | | | | 22/06/19 | | | | | 22/06/28 | | | | | | 271,209 | | | 02/07/19 | | 02/07/19 | | | £ | 0.48 | | | 02/07/20 | | 02/07/29 | | ||||||||||||
| | | | 234,407 | | | | | 02/07/19 | | | | | 02/07/19 | | | | £ | 0.48 | | | | | 02/07/20 | | | | | 02/07/29 | | | | | | 197,678 | | | 01/07/20 | | 01/07/20 | | | £ | 1.35 | | | 01/07/21 | | 01/07/30 | | ||||||||||||
| | | | 184,258 | | | | | 01/07/20 | | | | | 01/07/20 | | | | £ | 1.35 | | | | | 01/07/21 | | | | | 01/07/30 | | | | | | 505,918 | | | 01/07/21 | | 01/07/21 | | | £ | 0.51 | | | 01/07/22 | | 01/07/31 | | ||||||||||||
| | | | 474,385 | | | | | 01/07/21 | | | | | 01/07/21 | | | | £ | 0.51 | | | | | 01/07/22 | | | | | 01/07/31 | | | | | | 816,067 | | | 01/07/22 | | 01/07/22 | | | £ | 0.23 | | | 01/07/23 | | 01/07/32 | | ||||||||||||
| | | | 737,050 | | | | | 01/07/22 | | | ��� | | 01/07/22 | | | | £ | 0.23 | | | | | 01/07/23 | | | | | 01/07/32 | | | | | | 1,077,756 | | | 03/07/23 | | 03/07/23 | | | £ | 0.12 | | | 03/07/24 | | 03/07/33 | | ||||||||||||
Total | | | | 2,734,336 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,983,256 | | | | | | | | | | | | | | | | ||||||||||||
Tal Zaks(3) | | | | 288,000 | | | | | 29/11/16 | | | | | 29/11/16 | | | | £ | 0.65 | | | | | 29/11/17 | | | | | 29/11/26 | | | |||||||||||||||||||||||||||||||
Ali Behbahani | | | | 155,682 | | | 11/05/15 | | 11/05/15 | | | £ | 1.82 | | | 11/05/15 | | 11/05/25 | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 184,562 | | | 11/08/16 | | 11/08/16 | | | £ | 0.97 | | | 11/08/17 | | 11/08/26 | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 220,788 | | | 03/07/17 | | 03/07/17 | | | £ | 0.58 | | | 03/07/18 | | 03/07/27 | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 144,000 | | | | | 03/07/17 | | | | | 03/07/17 | | | | £ | 0.58 | | | | | 03/07/18 | | | | | 03/07/27 | | | | | | 154,809 | | | 22/06/18 | | 22/06/18 | | | £ | 1.65 | | | 22/06/19 | | 22/06/28 | | ||||||||||||
| | | | 124,000 | | | | | 22/06/18 | | | | | 22/06/18 | | | | £ | 1.65 | | | | | 22/06/19 | | | | | 22/06/28 | | | | | | 234,407 | | | 02/07/19 | | 02/07/19 | | | £ | 0.48 | | | 02/07/20 | | 02/07/29 | | ||||||||||||
| | | | 124,000 | | | | | 02/07/19 | | | | | 02/07/19 | | | | £ | 0.48 | | | | | 02/07/20 | | | | | 02/07/29 | | | | | | 184,258 | | | 01/07/20 | | 01/07/20 | | | £ | 1.35 | | | 01/07/21 | | 01/07/30 | | ||||||||||||
| | | | 144,000 | | | | | 01/07/20 | | | | | 01/07/20 | | | | £ | 1.35 | | | | | 01/07/21 | | | | | 01/07/30 | | | | | | 474,385 | | | 01/07/21 | | 01/07/21 | | | £ | 0.51 | | | 01/07/22 | | 01/07/31 | | ||||||||||||
| | | | 379,788 | | | | | 01/07/21 | | | | | 01/07/21 | | | | £ | 0.51 | | | | | 01/07/22 | | | | | 01/07/31 | | | | | | 737,050 | | | 01/07/22 | | 01/07/22 | | | £ | 0.23 | | | 01/07/23 | | 01/07/32 | | ||||||||||||
| | | | 500,000 | | | | | 01/07/22 | | | | | 01/07/22 | | | | £ | 0.23 | | | | | 01/07/23 | | | | | 01/07/32 | | | | | | 933,317 | | | 03/07/23 | | 03/07/23 | | | £ | 0.12 | | | 03/07/24 | | 03/07/33 | | ||||||||||||
Total | | | | 1,703,788 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,279,258 | | | | | | | | | | | | | | | | ||||||||||||
Barbara Duncan(4) | | | | 332,776 | | | 23/06/16 | | 23/06/16 | | | £ | 1.01 | | | 23/06/17 | | 23/06/26 | | |||||||||||||||||||||||||||||||||||||||||||
| | | | | 228,765 | | | 03/07/17 | | 03/07/17 | | | £ | 0.58 | | | 03/07/18 | | 03/07/27 | | ||||||||||||||||||||||||||||||||||||||||||
| | | | 158,233 | | | 22/06/18 | | 22/06/18 | | | £ | 1.65 | | | 22/06/19 | | 22/06/28 | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 124,000 | | | 02/07/19 | | 02/07/19 | | | £ | 0.48 | | | 02/07/20 | | 02/07/29 | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 144,000 | | | 01/07/20 | | 01/07/20 | | | £ | 1.35 | | | 01/07/21 | | 01/07/30 | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 379,788 | | | 01/07/21 | | 01/07/21 | | | £ | 0.51 | | | 01/07/22 | | 01/07/31 | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 500,000 | | | 01/07/22 | | 01/07/22 | | | £ | 0.23 | | | 01/06/23 | | 01/07/32 | | |||||||||||||||||||||||||||||||||||||||||||
Total | | | | 1,867,562 | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
John Furey(3) | | | | 284,233 | | | 05/07/18 | | 05/07/18 | | | £ | 1.49 | | | 05/07/19 | | 05/07/28 | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 240,541 | | | 02/07/19 | | 02/07/19 | | | £ | 0.48 | | | 02/07/20 | | 02/07/29 | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 196,186 | | | 01/07/20 | | 01/07/20 | | | £ | 1.35 | | | 01/07/21 | | 01/07/30 | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 379,788 | | | 01/07/21 | | 01/07/21 | | | £ | 0.51 | | | 01/07/22 | | 01/07/31 | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 500,000 | | | 01/07/22 | | 01/07/22 | | | £ | 0.23 | | | 01/07/23 | | 01/07/32 | |
Name of Director | | | Options Held | | | Grant date | | | Start date for vesting | | | Exercise price | | | First date of exercise of some or all options(1) | | | Date of expiry | | ||||||
| | | | | 500,000 | | | | 03/07/23 | | | 03/07/23 | | | | £ | 0.12 | | | | 03/07/24 | | | 03/07/33 | |
Total | | | | | 2,100,748 | | | | | | | | | | | | | | | | | | | | |
Priti Hegde(2) | | | | | 500,000 | | | | 03/07/23 | | | 03/07/23 | | | | £ | 0.12 | | | | 03/07/24 | | | 03/07/33 | |
| | | | | 226,464 | | | | 05/07/23 | | | 05/07/23 | | | | £ | 1.39 | | | | 05/07/23 | | | 24/08/31 | |
| | | | | 109,746 | | | | 05/07/23 | | | 05/07/23 | | | | £ | 0.46 | | | | 05/07/23 | | | 08/12/31 | |
| | | | | 152,376 | | | | 05/07/23 | | | 05/07/23 | | | | £ | 0.09 | | | | 15/12/23 | | | 14/12/32 | |
Total | | | | | 988,586 | | | | | | | | | | | | | | | | | | | | |
Kristen Hege(3) | | | | | 1,000,000 | | | | 01/11/23 | | | 01/11/23 | | | | £ | 0.07 | | | | 01/11/24 | | | 01/11/33 | |
Total | | | | | 1,000,000 | | | | | | | | | | | | | | | | | | | | |
Garry Menzel(2) | | | | | 981,463 | | | | 03/07/23 | | | 03/07/23 | | | | £ | 0.12 | | | | 03/07/24 | | | 03/07/33 | |
| | | | | 1,251,966 | | | | 05/07/23 | | | 05/07/23 | | | | £ | 0.07 | | | | 05/07/23 | | | 07/12/27 | |
| | | | | 359,700 | | | | 05/07/23 | | | 05/07/23 | | | | £ | 0.51 | | | | 05/07/23 | | | 25/07/28 | |
| | | | | 3,568,026 | | | | 05/07/23 | | | 05/07/23 | | | | £ | 0.51 | | | | 05/07/23 | | | 26/07/28 | |
| | | | | 57,846 | | | | 05/07/23 | | | 05/07/23 | | | | £ | 0.46 | | | | 05/07/23 | | | 08/12/31 | |
| | | | | 2,715,816 | | | | 05/07/23 | | | 05/07/23 | | | | £ | 0.46 | | | | 05/07/23 | | | 08/12/31 | |
| | | | | 2,158,776 | | | | 05/07/23 | | | 05/07/23 | | | | £ | 0.09 | | | | 05/07/23 | | | 14/12/32 | |
Total | | | | | 11,093,593 | | | | | | | | | | | | | | | | | | | | |
James Noble(5) | | | | | 3,500,000 | | | | 20/03/15 | | | 19/12/14 | | | | £ | 0.3557 | | | | 19/12/15 | | | 19/12/24 | |
| | | | | 1,968,016 | | | | 18/01/16 | | | 18/01/16 | | | | £ | 0.89 | | | | 18/01/17 | | | 18/01/26 | |
| | | | | 1,641,106 | | | | 13/01/17 | | | 13/01/17 | | | | £ | 0.59 | | | | 13/01/18 | | | 13/01/27 | |
| | | | | 931,632 | | | | 12/01/18 | | | 12/01/18 | | | | £ | 0.96 | | | | 12/01/19 | | | 12/01/28 | |
| | | | | 192,060 | | | | 12/01/18 | | | 12/01/18 | | | | £ | 0.001 | | | | 12/01/19 | | | 12/01/28 | |
| | | | | 140,448 | | | | 04/01/19 | | | 04/01/19 | | | | £ | 0.001 | | | | 04/01/20 | | | 04/01/29 | |
| | | | | 733,698 | | | | 04/01/19 | | | 04/01/19 | | | | £ | 0.70 | | | | 04/01/20 | | | 04/01/29 | |
| | | | | 31,000 | | | | 01/04/20 | | | 01/04/20 | | | | £ | 0.36 | | | | 01/04/21 | | | 01/04/30 | |
| | | | | 179,785 | | | | 01/07/20 | | | 01/07/20 | | | | £ | 1.35 | | | | 01/07/21 | | | 01/07/30 | |
| | | | | 379,788 | | | | 01/07/21 | | | 01/07/21 | | | | £ | 0.51 | | | | 01/07/22 | | | 01/07/31 | |
| | | | | 710,711 | | | | 01/07/22 | | | 01/07/22 | | | | £ | 0.23 | | | | 01/06/23 | | | 01/07/32 | |
Total | | | | | 10,408,244 | | | | | | | | | | | | | | | | | | | | |
Elliott Sigal(6) | | | | | 519,481 | | | | 16/03/15 | | | 16/03/15 | | | | £ | 0.50 | | | | 16/03/16 | | | 16/03/25 | |
| | | | | 24,596 | | | | 11/05/15 | | | 11/05/15 | | | | £ | 1.82 | | | | 11/05/15 | | | 11/05/25 | |
| | | | | 184,562 | | | | 11/08/16 | | | 11/08/16 | | | | £ | 0.97 | | | | 11/08/17 | | | 11/08/26 | |
| | | | | 220,788 | | | | 03/07/17 | | | 03/07/17 | | | | £ | 0.58 | | | | 03/07/18 | | | 03/07/27 | |
| | | | | 154,809 | | | | 22/06/18 | | | 22/06/18 | | | | £ | 1.65 | | | | 22/06/19 | | | 22/06/28 | |
| | | | | 234,407 | | | | 02/07/19 | | | 02/07/19 | | | | £ | 0.48 | | | | 02/07/20 | | | 02/07/29 | |
| | | | | 184,258 | | | | 01/07/20 | | | 01/07/20 | | | | £ | 1.35 | | | | 01/07/21 | | | 01/07/30 | |
| | | | | 474,385 | | | | 01/07/21 | | | 01/07/21 | | | | £ | 0.51 | | | | 01/07/22 | | | 01/07/31 | |
| | | | | 737,050 | | | | 01/07/22 | | | 01/07/22 | | | | £ | 0.23 | | | | 01/07/23 | | | 01/07/32 | |
| | | | | 933,317 | | | | 03/07/23 | | | 03/07/23 | | | | £ | 0.12 | | | | 31/10/23 | | | 03/07/33 | |
Total | | | | | 3,667,653 | | | | | | | | | | | | | | | | | | | | |
Tal Zaks(7) | | | | | 288,000 | | | | 29/11/16 | | | 29/11/16 | | | | £ | 0.65 | | | | 29/11/17 | | | 29/11/26 | |
| | | | | 144,000 | | | | 03/07/17 | | | 03/07/17 | | | | £ | 0.58 | | | | 03/07/18 | | | 03/07/27 | |
Name of Director | | | Options Held | | | Grant date | | | Start date for vesting | | | Exercise price | | | First date of exercise of some or all options(1) | | | Date of expiry | | ||||||
| | | | | 124,000 | | | | 22/06/18 | | | 22/06/18 | | | | £ | 1.65 | | | | 22/06/19 | | | 22/06/28 | |
| | | | | 124,000 | | | | 02/07/19 | | | 02/07/19 | | | | £ | 0.48 | | | | 02/07/20 | | | 02/07/29 | |
| | | | | 144,000 | | | | 01/07/20 | | | 01/07/20 | | | | £ | 1.35 | | | | 01/07/21 | | | 01/07/30 | |
| | | | | 379,788 | | | | 01/07/21 | | | 01/07/21 | | | | £ | 0.51 | | | | 01/07/22 | | | 01/07/31 | |
| | | | | 500,000 | | | | 01/07/22 | | | 01/07/22 | | | | £ | 0.23 | | | | 29/03/23 | | | 01/07/32 | |
Total | | | | | 1,703,788 | | | | | | | | | | | | | | | | | | | | |
|
Period | | Single total figure of remuneration $(1) | | Annual bonus payout against maximum opportunity(2) | | Long term incentive vesting rates against maximum opportunity(3) | | | Single total figure of remuneration $(1) | | Annual bonus payout against maximum opportunity(2) | | Long term incentive vesting rates against maximum opportunity(3) | | ||||||||||||||||||||||||
Year ended 31 December 2023: | | | | 1,613,184 | | | | | 57% | | | | | 100% | | | ||||||||||||||||||||||
Year ended 31 December 2022: | | | | 1,320,667 | | | | | —% | | | | | 100% | | | | | | 1,320,667 | | | | | —% | | | | | 100% | | | ||||||
Year ended 31 December 2021: | | | | 1,756,695 | | | | | 57% | | | | | 100% | | | | | | 1,756,695 | | | | | 57% | | | | | 100% | | | ||||||
Year ended 31 December 2020: | | | | 1,401,252 | | | | | 66% | | | | | 100% | | | | | | 1,401,252 | | | | | 66% | | | | | 100% | | | ||||||
Year ended 31 December 2019: | | | | 512,423 | | | | | 35% | | | | | 100% | | | | | | 512,423 | | | | | 35% | | | | | 100% | | | ||||||
Year ended 31 December 2018: | | | | 772,600 | | | | | 47% | | | | | 100% | | | | | | 812,708 | | | | | 47% | | | | | 100% | | | ||||||
Year ended 31 December 2017: | | | | 741,418 | | | | | 45% | | | | | 100% | | | | | | 779,907 | | | | | 45% | | | | | 100% | | | ||||||
Year ended 31 December 2016: | | | | 496,644 | | | | | 50% | | | | | 100% | | | | | | 522,426 | | | | | 50% | | | | | 100% | | | ||||||
Year ended 31 December 2015: | | | | 625,372 | | | | | 100% | | | | | 100% | | | | | | 657,836 | | | | | 100% | | | | | 100% | | |
| | CEO(1) | | Average change per employee(2) | | | CEO(1) | | Average change per employee(2) | | ||||||||||||||||
Base salary | | | | 5.3% | | | | | (0.9)% | | | | | | 0.0% | | | | | 5.3% | | | ||||
Annual bonus | | | | (100.0)% | | | | | (40.7)% | | | | | | 100.0% | | | | | 96.1% | | | ||||
Taxable benefits | | | | 8.0% | | | | | 22.9%(3) | | | | | | (18.1)% | | | | | 4.1%(3) | | |
| | Barbara Duncan(1) | | James Noble(2) | | John Furey(3) | | Tal Zaks(4) | | Average change per employee(5) | | | Barbara Duncan(1) | | John Furey(2) | | Tal Zaks(3) | | Average change per employee(4) | | ||||||||||||||||||||||||||||||||||||
Fees and base salary | | | | 0.0% | | | | | 0.0% | | | | | 100.0% | | | | | 0.0% | | | | | (0.9)% | | | | | | (58.3)% | | | | | 0.0% | | | | | (75.0)% | | | | | 5.3% | | | |||||||||
Annual bonus | | | | —% | | | | | —% | | | | | —% | | | | | —% | | | | | (40.7)% | | | | | | —% | | | | | —% | | | | | —% | | | | | 96.1% | | | |||||||||
Taxable benefits | | | | —% | | | | | —% | | | | | —% | | �� | | | | —% | | | | | 22.9% | | | | | | —% | | | | | —% | | | | | —% | | | | | 4.1% | | |
Financial Year | | | Method | | | 25th percentile pay ratio | | | Median pay ratio | | | 75th percentile pay ratio | | |||||||||
2023 | | | Option A | | | | | 26:1 | | | | | | 21:1 | | | | | | 16:1 | | |
2022 | | | Option A | | | | | 26:1 | | | | | | 20:1 | | | | | | 15:1 | | |
2021 | | | Option A | | | | | 31:1 | | | | | | 24:1 | | | | | | 17:1 | | |
Financial Year | | | CEO | | | 25th percentile | | | Median | | | 75th percentile | | ||||||||||||
2022 Salary ($) | | | | | 650,000 | | | | | | 44,781 | | | | | | 56,914 | | | | | | 74,291 | | |
2022 Total Remuneration ($) | | | | | 1,320,666(1) | | | | | | 50,460 | | | | | | 64,450 | | | | | | 86,730 | | |
Financial Year | | | CEO | | | 25th percentile | | | Median | | | 75th percentile | | ||||||||||||
2023 Salary ($) | | | | | 650,000 | | | | | | 53,846 | | | | | | 65,884 | | | | | | 86,573 | | |
2023 Total Remuneration ($) | | | | | 1,613,184(1) | | | | | | 62,058 | | | | | | 78,300 | | | | | | 103,325 | | |
Period: | | Year ended 31 December 2022 | | Year ended 31 December 2021 | | | Year ended 31 December 2023 | | Year ended 31 December 2022 | | ||||||||||||||||
Total spend on remuneration(1): | | | $ | 92,562,000 | | | | $ | 86,135,000 | | | | | $ | 89,178,000 | | | | $ | 92,562,000 | | | ||||
Research and development expenses: | | | $ | 155,163,000 | | | | $ | 139,799,000 | | | | | $ | 144,272,000 | | | | $ | 155,163,000 | | |
Resolution | | Votes For | | % of Total | | Votes Against | | % of Total | | Votes Withheld | | % of Total | | | Votes For | | % of Total | | Votes Against | | % of Total | | Votes Withheld | | % of Total | | ||||||||||||||||||||||||||||||||||||||||||||||||
To approve the Directors’ Remuneration Report | | | | 679,237,246 | | | | | 98.56 | | | | | 9,914,362 | | | | | 1.44 | | | | | 23,574,640 | | | | | 3.42 | | | | | | 726,972,352 | | | | | 99.54 | | | | | 3,339,912 | | | | | 0.46 | | | | | 468,756 | | | | | 0.06 | | | ||||||||||||
To approve the Directors’ Remuneration Policy (2021 AGM) | | | | 661,140,212 | | | | | 99.50 | | | | | 3,293,250 | | | | | 0.50 | | | | | 333,102 | | | | | 0.05 | | |
Element of Remuneration | | | Purpose and link to strategy | | | Operation | | | Maximum | | | Performance targets | |
Base salary | | | Rewards skills and experience and provides the basis for a competitive remuneration package. | | | Salaries will typically be reviewed |
experience and scope of the role; (iii) broader employee Salaries will be benchmarked against comparable roles in a selected peer group of US- and European-listed biopharmaceutical companies with similar market capitalisations and/or scale of operational complexity. We typically expect to align salaries with the 50th percentile of peer group comparator data but may vary from this general rule where we consider that special circumstances apply or where recruitment or retention of a particular role is required. The Committee | | | Salaries will not generally exceed the 75th percentile of peer group comparator data for the relevant role unless there is a clear business rationale to do so. The Committee will reference alternative data for roles not widely represented in the core peer group. The Committee retains discretion to adjust the Executive Directors’ base salaries to ensure that we can attract and retain the necessary talent to effectively compete in the global marketplace. | | | Not applicable. | |
Element of Remuneration | | | Purpose and link to strategy | | | Operation | | | Maximum | | | Performance targets | |
| | | | | | The Committee may also decide to approve future increases following changes to job responsibilities or to reflect experience within the role. | | | | | | | |
Pension | | | Enables Executive Directors to build long-term retirement savings. | | | Company contribution to a personal pension scheme or a pension allowance payment, at the election of the Executive Director. Levels will be reviewed annually and the Committee may decide to increase future contribution levels should the review indicate such a change is appropriate. Executive Director pension levels will be aligned to the pension rate made available to the wider workforce, which, at the time of the development of the remuneration policy, is 6% of base salary. | | | Currently 6% of The Committee may increase Executive Director pension levels to align with the rate made available to the wider workforce. | | | Not applicable. | |
Benefits | | | | | Benefits currently include death-in-service life insurance, family private medical cover and ill-health income protection. The Committee will review benefits offered from time to time and retains the discretion to add or substitute benefits to ensure they remain market competitive. In the event that the Group requires an Executive Director to relocate, | | | | | Not applicable. | | ||
Annual Bonus | | | Rewards achievement of the near-term business objectives set at the start of each calendar year and reflects individual and team performance of the Executive Director and other Senior Executives in achieving those objectives, and progress towards achieving our strategic goals. | | | Objectives are set at the start of each calendar year. The choice of annual performance objectives will reflect the Committee’s assessment of the key milestones/metrics required to be achieved within the calendar year in order to make progress towards achieving our strategic goals. The target annual cash bonus for our Executive Directors The annual bonus is typically payable in cash | | | Awards will normally be limited to a maximum of 100% of In exceptional periods, considered to be those years in which achievements lead to a transformational effect on the future prospects or the valuation of the business, the annual maximum may increase to up to 150% of basic salary. Judgement as to | | | The Committee retains the ability to set performance objectives annually. These objectives can be group-based and /or individual, financial and/ or non-financial, and are likely to include milestones linked to: • successful execution of key elements of pipeline development programmes; | |
Element of Remuneration | | | Purpose and link to strategy | | | Operation | | | Maximum | | | Performance targets | |
| | | | | | end. In exceptional circumstances the Committee may determine that all or part of the bonus will be paid in shares or share options. When business opportunities or challenges change substantially during the course of the year, the Committee may adjust objectives to meet the changed circumstances and correspondingly realign potential rewards. Awards may be subject to clawback (see Notes to policy tables). | | | whether achievements in a calendar year are considered to be exceptional is at the discretion of the Committee. | | | • progress with clinical trials programmes; • key regulatory steps (IND grants, regulatory approvals); • progress with business development activities; • the Group’s financial position and equity liquidity and valuation. |
A number of these objectives are considered to be commercially sensitive and are therefore not disclosed here in detail. | | ||||||||||||
Long term equity incentives | | | Motivates and rewards multi-year performance, encouraging achievement of strategy over the medium to long term. Aligns the interests of our Executive Directors and Senior Executives with those of our shareholders. Encourages retention as entitlement to full benefits arising from equity-based awards only accrues over a period of years. Enables us to compete with equity-based remuneration offered by a set of comparable companies with whom we may compete for executive talent. | | | Under our share option schemes, the Committee is able to grant awards of CSOP options in the UK, and unapproved share options (non-qualifying options) in the UK and US, which includes the ability to grant RSU-style awards. The Committee may grant other forms of equity award in relation to shares in the Company, subject to shareholder approval if required. All awards may be subject to performance targets. The Committee generally grants equity-based remuneration to Executive Directors and Senior Executives at the time they commence employment and from time to time thereafter based on performance. The Committee The Committee may determine that a different vesting schedule is | | | There is no fixed annual maximum limit to the size or value of equity- based compensation awards made in a year to Executive Directors and Senior Executives, or in the aggregate over a However, the Committee will always work within benchmarking guidelines provided by our compensation consultants. Additionally, our option scheme rules set a maximum limit on the grant of options to all participants of 8% of our initial issued share capital on the date of our IPO increased by 4% on each 30 June to be effective from 1 July 2016. | | | Generally, we grant equity-based remuneration awards that vest over time without specific performance targets other than continued service. Awards may be subject to performance targets at the discretion of the Committee. When making awards, the Committee considers: the size and value of past awards; the performance of the Executive Director and Senior Executives; and competitive data on awards made to executives at comparable companies. Our Severance Policy entitles the Executive Director and Senior Executives to | |
Element of Remuneration | | | Purpose and link to strategy | | | Operation | | | Maximum | | | Performance targets | |
| | | | | | appropriate, in which case the different vesting schedule will be disclosed at the time the awards are made. Awards may be subject to clawback (see Notes to policy tables). | | | Expected values are calculated in accordance with generally accepted methodologies based on Black-Scholes models. We seek to establish equity-based remuneration to be reasonably competitive to that offered by a set of comparable companies with whom we may compete for executive talent. | | | Additionally, the Board has discretion to accelerate vesting of options including in connection with a change of control event or when an Executive Director’s service is terminated on account of disability or death. See Policy on Payments for Loss of Office. | |
| Minimum | | | The base salary for the Executive Director is assumed to be the base salary of | |
| | | | The value of benefits receivable for the year ending 31 December | |
| | | | No bonus is assumed for the Executive Director. The value of the equity-based awards is assumed to be zero. | |
| In line with | | | The same components for base salary and benefits as reflected for the minimum above. | |
| | | | The expected level of bonus is taken to be 60% of base salary, being the target level of bonus payment for the year ending 31 December | |
| | | | the equity-based awards is assumed to be the intrinsic value (based on the market value of the underlying shares at the grant date less the exercise price) of the share options granted to the Executive Director during the year ended 31 December | |
| Maximum | | | The same components for base salary and benefits as reflected for the minimum above. | |
| | | | The maximum level of bonus is taken to be 100% of current base salary. The same value for the equity-based awards as for the “In line with expectations” scenario above. | |
| Maximum plus 50% increase | | | The same components for base salary, benefits and bonus as reflected for the maximum above. | |
| | | | The value of the equity-based awards is assumed to be the intrinsic value calculated as above, but based on an assumption that the underlying shares granted have increased in value by 50% since the grant date. | |
Name | | | Position | | | Date of agreement | | | Notice period | |
Adrian Rawcliffe | | | Chief Executive Officer | | | 26 June 2019 | | | At will (Company) / 60 days (Director) | |
Element of Remuneration | | | Purpose and link to strategy | | | Operation | | | Maximum | | | Performance targets | |
Non-Executive fees | | | Reflects time commitments and responsibilities of each role. Reflects fees paid by similarly sized companies. | | | The remuneration of the Non-Executive Directors will be determined by the Board as a whole and is informed by reference to (i) market practice and market data, on which the Committee receives independent We typically expect to align fees with the 50th percentile of peer group comparator data but may vary from this general rule where we consider that special circumstances apply or where | | | The value of each individual’s aggregate fees will not exceed the 75th percentile of peer group comparator data for the relevant role, unless there is a clear business rationale to do so. | | | None. | |
Element of Remuneration | | | Purpose and link to strategy | | | Operation | | | Maximum | | | Performance targets | |
| | | | | | recruitment or retention of a particular role is required. Fees will typically consist of a basic fee for Non-Executive Director responsibilities plus incremental fees for additional | |||||||
roles/responsibilities such as membership and chairmanship of Board committees and a senior independent Non-Executive Director role. The Non-Executive Directors may elect to receive the fees in cash or in the form of an award of additional share The Non-Executive Directors do not receive any pension from the Company, nor do they participate in any performance-related incentive plans. | | | | | | | | ||||||
| | To reimburse Directors for reasonable expenses incurred. | | | Non-Executive Directors do not participate in any Company pension plan. Non-Executive Directors may receive travel, accommodation and other business-related expenses incurred in carrying out the role. | | | No formal maximum. | | | None. | | |
Equity Awards | | | For public companies listed in the United States, equity-based remuneration is a standard component of Director remuneration. We extend equity-based awards to our Non-Executive Directors in order to be competitive with comparable companies seeking qualified | | | Non-Executive Directors participate in the Group’s long-term incentive plans on terms similar to those used for Executive Directors. Under their appointment letters, each Non-Executive |
Director is entitled to receive an annual award of options, provided that he or she continues to serve as a Director. When a new Non-Executive Director is appointed, he or she may receive an initial award of options. In either scenario, these may include unapproved options (non-qualified options) and RSU-style awards. The Board may grant other forms of equity award in relation to shares in the | | | No formal maximum. The equity awards will be determined by the Board as a whole working within benchmarking guidelines provided by our compensation consultants and taking account of US market practice, responsibilities, and ongoing time commitment. | | | Not performance- related. | |
Element of Remuneration | | | Purpose and link to strategy | | | Operation | | | Maximum | | | Performance targets | |
| | | Directors and to align the interests of our Non- Executive Directors with those of our shareholders. | | | Company, subject to shareholder approval if required. The Board is able to grant share options which permit phased vesting over the period. Currently, options awarded to new Directors become fully exercisable over three years while options awarded annually are exercisable on the first anniversary of the date of grant. Other vesting schedules may be adopted at the discretion of the Board. Any share options awarded will not be subject to performance conditions. Expected values are calculated in accordance with generally accepted methodologies based on Black-Scholes models. | | | Additionally, our option scheme rules set a maximum limit on the grant of options to all participants of 8% of our initial issued share capital on the date of our IPO increased by 4% on each 30 June effective from 1 July 2016. | | | | |